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Multiple Sclerosis (MS) is a complex autoimmune and neurodegenerative disease 
affecting more than 1 in 1000 people. The disease is characterized by T and B 
lymphocytes attacking the central nervous system, leading to demyelination. This can 
lead to symptoms affecting the motor function and can result in permanent disability. 
Epstein-Barr virus (EBV) has been implicated in MS with universal presence and elevated 
EBV antibody titres in MS patients. The role of B lymphocytes has become of major 
interest with beneficial effects of B lymphocyte-depleting agents and studies 
demonstrating increased autoreactive memory-B lymphocytes in MS patients. While 
EBV is known to reside in B lymphocytes, due to the low EBV copy number during 
latency it is unknown in which B lymphocyte subset EBV is residing in and if the quantity 
of EBV infected lymphocytes differs between B lymphocyte subsets in MS patients and 
healthy controls. The use of a specific and sensitive method to quantitate EBV latency in 
B lymphocyte subsets is yet to be determined and is the focus of this research study. Three 
independent methods were compared: Quantitative polymerase chain reaction (qPCR), 
digital droplet polymerase chain reaction (ddPCR) and flow cytometry coupled with 
fluorescent in situ hybridization (Flow-FISH) targeting EBV Nuclear Antigen-1 (EBNA-
1) and EBER (small viral RNAs), respectively. We have successfully quantified EBNA-
1 and EBER in healthy control samples with the techniques qPCR and flow-FISH, 
respectively. However, as a result of the sequence homology between EBNA-1 and 
genomic DNA, ddPCR was determined to be too non-specific as it did not quantify target 
EBNA-1. Phenotyping latently EBV infected lymphocytes could be used in the future as 
a biomarker for MS diagnosis and to target B lymphocyte depletion therapy more 
specifically to EBV infected or reactive lymphocytes, limiting side effects and improving 
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Multiple Sclerosis (MS) is a complex autoimmune and neurodegenerative disease 
characterized by T and B lymphocytes attacking the central nervous system, leading to 
demyelination. This can result in loss of motor control, vision and vertigo and can lead to 
permanent disability afflicting more than 1 in 1000 people. Epstein-Barr virus (EBV) has 
been implicated in MS pathogenesis in many investigations including our own research 
group, demonstrating universal presence of EBV antibodies in MS patients and 
additionally elevated EBV antibody titres in MS patients compared to controls. While 
initial research focussed on T lymphocytes, the role of B lymphocytes has become of 
major interest with the demonstration of beneficial effects of B lymphocyte depleting 
agents in MS patients. 
EBV is a human herpesvirus that is prevalent in up to 90% of the human population. 
During the post-infectious stage, the virus enters latency and lies dormant within B 
lymphocytes with intermittent reactivation. Research has revealed increased autoreactive 
memory B lymphocytes in peripheral blood and cerebrospinal fluid of MS patients (1–3). 
These autoreactive B lymphocytes can clonally expand within organs, such as the nervous 
system, and trigger autoimmune reactions by producing antibodies that bind myelin, 
leading to degradation.  
Furthermore, several studies investigating the association between EBV and MS have 
discovered symptomatic infection with EBV causing infectious mononucleosis and late 
infection in life are linked to MS development (4,5). Additional evidence for the 
importance of EBV in MS pathogenesis is the presence of oligoclonal bands, which are 
high titers of EBV-specific immunoglobulins specifically observed in the cerebrospinal 
fluid of MS patients and therefore was used as a diagnostic tool for MS (6,7). For both T 
and B lymphocytes, molecular mimicry results have been described. T lymphocyte 
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mimicry occurs if the immune system incorrectly cross-recognizes self-antigens in the 
brain as part of the immune response (8–10), whilst the mechanism for B lymphocyte 
mimicry includes EBV cross-reactive antibodies against myelin oligodendrocyte protein 
(11,12). 
EBV persists latently in B lymphocytes and memory B lymphocytes have been discussed 
as the main reservoir for the virus. Whilst it has been shown in a study by Chaganti, et 
al., that EBV resides in other B lymphocyte subsets in latent healthy controls (13), it is 
unknown if the quantity of EBV infected lymphocytes differs between subsets in MS 
patients and healthy controls. Lastly, EBV viral load, and therefore lytic replication, has 
not been implicated as a direct cause for MS symptoms, and therefore investigation of 
latent reservoirs would be of immediate research interest. Unfortunately, viral detection 
in latency is very difficult and there is currently no single known marker available for the 
identification of EBV in live cells.  
We hypothesize sensitive EBV quantification coupled with B lymphocyte subset 
targeting will allow the determination of significant differences in the viral load ratio 
between different B lymphocyte subsets. If this ratio is compared between MS and 
healthy controls, a specific EBV-infected B lymphocyte subset in MS will be known. 
EBV quantities in subsets might inform as a biomarker for future MS diagnosis. 
Additionally, identifying and characterising latently EBV infected lymphocytes could be 
used in the future to target B lymphocyte depletion therapy more specifically for a subset 




 Multiple Sclerosis (MS) 
3.1 MS disease progression 
During the disease progression of MS, the myelin surrounding the nerves in the central 
nervous system (CNS) is significantly damaged due to autoimmunity. The white matter 
and the cortical grey matter of the CNS display histological abnormalities, including 
inflammatory cell infiltration and physical lesions upon autopsy (14,15). When the 
myelin degenerates, the axons of nerves are exposed and action potentials are interrupted 
due to exposed ion channels (16–19). These demyelinated or inflamed areas may be 
visible on magnetic resonance imaging (MRI) scans and are referred to as ‘lesions’ in this 
context (19). Of note, a third of patients may only have benign clinically ‘silent’ lesions 
with no accompanying symptoms (20). As a result of demyelination, nerve impulses are 
slowed, and with subsequent axonal loss associated with disease progression, do not reach 
the synapse, and therefore the target muscle, leading to a loss of muscle control as the 
nerve cannot sustain a functional motor impulse. 
Long-term, muscle atrophy frequently occurs due to the lack of stimulation by action 
potentials. This absence of action potential makes movement harder for those suffering 
from the disease (21). Walking aids are often required to assist with movement and 
patients can be severely disabled and at risk of falling (22).  The development of MS is 
typically a gradual worsening disability over a patient’s lifetime. This progression of 
disability decreases lifespan by an average of seven years according to a 60-year study in 
Norway, where mortality is three times higher in MS compared to controls (23).  
 
3.2 Clinical patterns of MS 
The progression of MS disease can be categorized by clinical patterns. The precursor 
category of MS is called clinically isolated syndrome (CIS), where a patient exhibits 
clinical symptoms indicative of MS for the first time, however, this is not a definite 
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diagnosis as MS does not always develop after this initial episode. As can be seen in 
Figure 3.1(a), the most common form of MS is the relapsing-remitting form of MS and is 
present in about 80% of patients. Relapsing-remitting MS is characterized by symptoms 
leading to a loss of motor function alternating with periods of recovery and no symptoms 
(24). It is currently unknown exactly why patients may relapse into MS disease. Next to 
relapsing-remitting, primary progressive and secondary progressive are distinct types of 
MS with various levels of symptoms and recovery periods, as illustrated in Figure 
3.1(b,c). Relapsing-remitting MS may progress into secondary progressive MS, as 
depicted in Figure 3.1(c) where the attacks are less regular but the disease gradually 
worsens with no remission (25). In contrast, primary progressive MS (Figure 3.1(b)) is 
the rarest form and occurs in only about 5% of patients (26). This form is characterized 
by a lack of early relapses or remissions but instead progressive worsening of disease 
(25). Clinically, these categories of MS can only be established after about 10 years of 
monitoring, but categorizing is required to administer the most appropriate treatment (27). 










Figure 3.1: Clinical patterns 
of Multiple Sclerosis (MS): 
(a) Relapsing-remitting MS 
involves intermittent 
relapses and remissions from 
early on. (b) Primary-
progressive is a gradual 
worsening over time with no 
remission. (c) Secondary-
progressive MS: The disease 
progressively worsens with 
no remission (132). Images 




3.3 MS diagnostics 
Diagnosis of MS involves a combination of tests, including magnetic resonance imaging 
(MRI), symptomatic testing and pathology analysis. As portrayed in Figure 3.2, the 
myelin damage resulting in lesions in the CNS can be directly visualised by MRI, which 
is the most commonly used tool for MS diagnosis (28). In addition to imaging, functional 
testing for the determination of disability levels in MS patients is often assessed under the 
Extended Disability Status Scale (EDSS) (29). The test measures walking ability but it is 
not designed to measure physical neurological symptoms such as visual problems, 
cognitive changes, motor control changes in other limbs than the legs, sensory response 
loss, balance, coordination, and bladder or bowel control (29).  
Figure 3.2: Magnetic resonance imaging (MRI) scan of a patient diagnosed with clinically 
definite multiple sclerosis. Note lesions in the frontal and parietal lobes (A) and lesions 
within the cortex (B) indicate areas of demyelination. (28). Images from Barkhof F., et 
al., 1997, Brain. 
Next to MRI analysis, pathological testing for additional confirmation of MS diagnosis is 
utilized. The inflammation of the CNS, a hallmark of MS, can be confirmed by harvesting 
cerebrospinal fluid (CSF) via lumbar puncture. CSF is subsequently assessed for 
immunoglobulin levels, a sign of the presence of immune cells in the brain (6). Generally, 
several diagnostic methods are used in conjunction to enable the correct diagnosis and 




3.4 MS treatment 
There is currently no cure for MS, nor is there a preventative vaccine available. 
Nonetheless, there are many treatments that can minimise the progression of the disease, 
but none have been proven to absolutely stop the disease in its tracks, reverse its effects 
or be effective without side effects. The most current forms of MS treatment are directed 
against the relapsing-remitting form of MS. Therapy for this type of MS includes 
immunotherapy medications such as interferon-beta 1 (IFN-β1) and glatiramer acetate.  
Clinical studies by Jacobs and Li have demonstrated reduced onslaught of MS symptoms 
when treatment with IFN-β1 is started at disease onset (30). IFN-β1 is known to inhibit 
immune cells from crossing the blood-brain barrier (30,31). Glatiramer acetate inhibits T 
helper lymphocytes from influencing neighbouring immune cells in MS (32,33) and if 
administered in early CIS, it reduces relapse and new lesion development in 33% of 
patients without side effects (34–36). However, there is no significant difference between 
IFN-β1 and glatiramer acetate in terms of relapse outcome and neither of these treatments 
completely inhibit the progression of MS in all patients (37). Immunotherapy medications 
such as IFN-ß1 and glatiramer acetate are not permanent therapies, however, recent drug 
trials are determining future treatments. 
A more recent medication verified for MS treatment includes natalizumab. Natalizumab, 
a monoclonal antibody specific for adhesion integrin alpha-4, is currently used in MS 
treatment to prevent the adhesion of inflammatory cells to the blood-brain barrier and gut 
wall, hence inhibiting the binding and entry of inflammatory cells into the CNS (38). 
Interestingly, a single case study by Sera and colleagues has shown that when natalizumab 
therapy was ceased there was a case of severe MS disease relapse to the point of mortality, 
with a huge influx of EBV-infected B lymphocytes in lesions in the CNS of the patient, 
which was analysed post-mortem (38). This disease relapse post-natalizumab has 
occurred before and it was further hypothesized that the use of B lymphocyte depletion 
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therapy post-natalizumab treatment would be beneficial (38,39). B lymphocyte depletion 
therapy has been further investigated in clinical trials. 
 
3.4.1 B lymphocyte depletion therapy for MS 
B lymphocyte depletion therapy has been successfully used in autoimmune diseases 
including rheumatoid arthritis, lupus, Sjogren's syndrome, and more recently, these drugs 
were tested on patients with MS. In the first clinical trials (phase II and III) (40,41), B 
lymphocyte depletion therapy using rituximab, ocrelizumab and ofatumumab have shown 
a promising effect in reducing the risk of MS relapse by decreasing inflammation. These 
three therapies are all monoclonal antibodies shown to successfully target B lymphocyte 
surface antigen CD20+ through different mechanisms of action, hence depleting B 
lymphocytes. A study by Palanichamy et al. discovered MS patients undergoing 
rituximab therapy had a significant reduction in B lymphocytes for more than 6 months 
(42). A further study detected decreased B lymphocyte markers in the CNS in MS patients 
(40). In animal models of multiple sclerosis, the disease progression was significantly 
reduced by the elimination of interleukin-6 (IL-6)-producing B lymphocytes, which 
coincided with the reduction in myelin antigen-specific helper Th1 and Th17 
lymphocytes (43,44). In randomized double-blind, placebo-controlled trials, where 
patients were treated exclusively with rituximab after switching from other first-line 
injectable therapies, there were reduced CNS lesions by 24 weeks, especially in younger 
patients (41,45,46). These studies are evidence for a potential future MS treatment in B 
lymphocyte depletion therapy and highlights the need for focused research into B 





 Aetiology of MS 
MS is an autoimmune disease characterized by the immune system attacking the myelin 
sheath of the CNS, however, the exact aetiology of this autoimmune attack in MS is 
unclear. Like for other autoimmune diseases, including lupus and rheumatoid arthritis, 
there is evidence in MS for a genetic predisposition and influence of environmental risk 
factors (47–49).  The most documented MS risk in the disease susceptibility gene on the 
human leukocyte antigen (HLA) DR (42,44), and in particular HLA-DRB1*1501, 
significantly increase the risk of developing MS. There is also a link between gender and 
autoimmune disease, where women are more susceptible to MS than men(52,53).While 
many environmental risk factors for MS have been described, including smoking (47), 
diet (54,55) and air pollution (56), the most significant environmental risk for MS in 
multiple studies include Vitamin D deficiency (48) and EBV infection (57).   
 
4.1 MS demographics 
There is evidence that individuals in countries with greater latitude are at increased risk 
of developing MS, which has been mainly attributed to lower exposure to sunshine and 
therefore, lower Vitamin D levels in individuals further away from the equator. The first 
association of MS and latitude was described as early as 1921 (58). According to the Atlas 
of MS 2013 data, countries distant from the equator, such as the United States of America, 
Russia, Germany and United Kingdom, have the highest number of people living with 
MS: 400,000, 150,000, 130,000 and 100,000 respectively (59) (Figure 8.1), but 
population densities were not given in this investigation. In Australia alone, 21,283 
people are living with MS (59) while Asian and African countries show the lowest 
number of people with MS which might be partially skewed by insufficient data reporting. 
Of note is the effect of latitude on MS, which is also observable across Australia. There 
are high numbers of MS patients in Tasmania, compared to Perth and Melbourne with 
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lowest incidences of MS in Northern Queensland (60). Data for Europe is typically 
aligned with this theory of latitude risk, such as Ireland, which has a higher incidence rate 
than the rest of the British Isles, according to a recent 292 patient study (61). However, 
an exception to the theory of latitude risk is Norway, where there are very low incidences 
of MS despite its latitude (62), which has been mainly attributed to a high Vitamin D 
intake with the diet (62). Of note, the effect of latitude seems to be true for early childhood 
exposure up to the age of 15, as shown in migration studies (63). Overall, MS is linked to 
latitude with the exception of nations where dietary consumption of Vitamin D is high. 
 
Figure 4.1: Global prevalence of MS. The greatest prevalence of MS is in developed 
countries such as Canada, Europe and the United States. The lowest known prevalence is 
in developing countries near the equator such as Russia, Middle East, Asia and South 
Americas (59). Image from Atlas of MS 2008 MS International Federation. 
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4.2 Genetic susceptibility to MS 
4.2.1 Human leukocyte antigen (HLA) alleles 
The human leukocyte antigen (HLA) is positioned on the surface of immune cells such 
as T and B lymphocytes. HLA Class I is located on the surface of all nucleated cells and 
HLA Class II is mainly situated on the surface of antigen-presenting cells (APCs), 
functioning in the processing of antigens and presenting them to T lymphocytes. The main 
genetic risk factor for MS susceptibility has been found in genome-wide association 
studies (64) to be HLA-DRB1*1501. This variant has been discovered to be significantly 
more present in MS patients than healthy controls in several studies from different 
countries including US, Australia and Europe (65). The allele frequency of this risk allele 
in MS may be a result of epigenetics that are affected by maternal origin, generational 
differences, sex-specific mechanisms and external environmental factors (66). The 
combination of EBV and HLA-DRB1*1501, or on their own, are known to increase the 
risk of developing MS (13,85). Due to structural similarities, HLA-DRB1*1501 on T 
lymphocytes recognise myelin basic protein (MBP) and EBV peptides such as EBV DNA 
polymerase in the CSF of MS patients (67,68). There are multiple potential cross-reactive 
targets identified to include HLADRB1*15-restricted epitopes, myelin and paranodal 
assembly proteins, all of which may be novel myelin antigens targeted by CD4+ T 
lymphocytes in MS patients (69). The targeting by the immune system of self-antigens, 
such as myelin, is called autoimmunity and may be due to molecular mimicry. 
 
4.3 Molecular mimicry  
Molecular mimicry occurs when a small protein (peptide) of a foreign molecule resembles 
a self-antigen, and hence cross-reactivity can occur. This hypothesis has now been 
confirmed by multiple studies, directly linking different EBV proteins, such as EBV 
nuclear antigen- 1 (EBNA-1), with MS through autoreactive targets in the CNS (8–10). 
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Prior to EBV infection, auto-reactive B lymphocytes in the bone marrow normally 
undergo deletion, however, during autoimmune disease this control breaks down and 
auto-reactive B lymphocytes clonally expand (70). In MS, molecular mimicry involves 
EBV, auto-reactive B lymphocytes that produce cross-reactive antibodies, and self-
myelin antigens such as those antibodies that have specificity for either myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein or proteolipid protein (10). EBV 
proteins have been shown by Lünemann, et al., to structurally mimic MBP and 
subsequently, the MBP is marked as a target antigen for T lymphocytes (8). These mimic 
EBV antigens may be expressed by EBV-infected autoimmune B lymphocytes as they 
clonally expand and migrate towards the CNS, where it is theorized that they pass the 
blood-brain barrier as B lymphocytes have been shown in the past to be present in MS 
lesions in the CNS (71,72). Clonally-expanded EBV antigen-specific T-helper 
lymphocytes and memory T lymphocytes may also contribute to MS by cross-recognition 
of self-antigens, such as myelin antigens, or by T cell receptor-independent bystander 
mechanisms (9,73,74). These CD4+ T lymphocytes may migrate to the CNS, attracted by 
cytokines released by autoreactive B lymphocytes existing in the CNS, and interact via 
MHC class II as the B lymphocyte presents the myelin self-antigens and expresses co-
stimulatory molecules (75–77). An investigation by Casiraghi, et al., presented evidence 
of the co-stimulation of T lymphocyte marker CD40+ causing an upregulation of CD4+ 
and CD8+ effector T cells in an animal model for MS during EBV latency, whilst there 
was a downregulation of suppressor T regulatory (Treg) lymphocytes (78). This is clear 
evidence of increasing autoimmune reactivity (78) to EBV proteins and CD8+ response 
in MS patients  (79). These increased inflammatory cells are attracted to the CNS and 
attack the myelin, causing demyelination and damage to the neuronal function. Whilst the 
risks of molecular mimicry in MS in relation to EBV are quite high, there is evidence that 




4.4 Epstein-Barr virus as a risk factor for MS 
4.4.1 Introduction to EBV 
EBV is a DNA virus belonging to the human herpesvirus (HHV) group, in which it is 
denoted as HHV-4. It has evolved alongside humans for millions of years. EBV, like 
other human herpes viruses, has a large and complex genome. The virus is comprised of 
double-stranded DNA encased in a nucleocapsid. Outside the nucleocapsid is the 
tegument, which is analogous to the matrix in other viruses. The tegument itself is 
surrounded by a lipid bilayer envelope which is embedded with glycoproteins such as 
gp350, gB, gH and gL enabling the virus to penetrate B lymphocytes (80,81). 
Approximately 90% of the human population is infected with EBV but primary infection 
rarely causes severe symptoms. In contrast, the primary infection can cause severe 
symptoms which then present as infectious mononucleosis or glandular fever. Mostly, 
EBV exists latently in humans and is transmitted via saliva, typically during early 
childhood or intimacy between adolescents. There is some evidence that EBV uses 
mechanisms during lytic phase to avoid the immune system prior to entering latency, 
including the inhibition of monocyte phagocytosis (82) and compromising T lymphocyte 
antiviral responses through precursor dendritic cell apoptosis (83), enabling it to persist. 
This persistence and effect on the immune system may lead EBV to be a key trigger of 
multiple autoimmune diseases such as MS, systemic lupus erythematosus and rheumatoid 




4.4.2 EBV and MS 
4.4.2.1 EBV antibody titres in MS patients 
EBV infection has been implicated to have a strong correlation with MS. The presence of 
high antibody activity specific for EBV has been detected in CSF and blood sample 
testing from MS patients in multiple studies (79,86,87). A study by Cepok, et al. observed 
significantly higher antibodies specific for EBV proteins EBNA-1 and BRRF2 in the CSF 
and serum of MS patients compared to controls (79). These results were also confirmed 
by two other groups for EBV antibodies in both serum and CSF (86,87). A single 
controversial study by Serafini and colleagues discerned MS patients’ brain tissues were 
infected with EBV (88). However, there were limitations to this study as they only 
investigated a small sample of 22 people, leading to controversy when peer reviewed (89) 
as no other group could replicate direct presence of EBV in postmortem samples. Despite 
this, there have been studies to show the reactivation of EBV into the lytic stage in MS 
patients, as compared to healthy EBV-seropositive individuals by EBV protein studies 
and MRI scans of the CNS for demyelination (90–92). EBV is a significant factor in MS 
aetiology and may be the key trigger of this disease.  
 
4.4.2.2 Oligoclonal Bands 
There is further evidence for a link between MS and EBV with the testing of CSF for 
increased levels of IgG protein during diagnostics. This protein forms oligoclonal bands, 
which are the only clinical biomarker currently used for MS diagnosis. IgG in MS patients 
has been found in some studies to be specific for EBER, however, this is not always the 
case, with low specificity in other research and equivalent specificity to other non-MS 
neurological diseases (6,7). 
Oligoclonal bands are produced by B lymphocytes, which is indicative of an 
inflammatory response in the CSF. The presence of the oligoclonal bands is telling of the 
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clonal expansion of B lymphocytes that occurs in the CSF; and as it is known that B 
lymphocytes undergo somatic hypermutation and class switching recombination when 
they are latently infected with EBV (87,93). It is theorized these B lymphocytes release 
antibodies with high affinity for the antigen in a process called affinity maturation, which 
leads to elevated levels of IgG and complement deposits in lesions. 
4.4.2.3 Infectious Mononucleosis and MS onset 
Infective mononucleosis (IM), the illness that arises due to infection with EBV, is 
significantly associated with MS development, as infection with EBV in older people 
often leads to symptoms presenting in IM and increases the risk of MS by about 2.3 fold 
(65) This illness can be catastrophic in immunosuppressed patients but is typically 
asymptomatic and harmless in healthy individuals. Symptoms of IM are characterized by 
fever, sore throat and swollen lymph nodes (94). These symptoms are caused by the 
inflammatory response of the 1-40% of CD8+ T lymphocytes specific for EBV antigen 
and the 10% of B lymphocytes that are infected with EBV virions (95). IM is a self-
limiting disease and symptoms rarely persist (94). However, it is hypothesised that there 
is a window of time during childhood when EBV infection occurs and MS subsequently 
may occur during a later stage of life (4). In multiple studies, MS patients from various 
countries were asked to recall their age when they had IM and it was shown that if 
infection occurred between puberty and the age of 18, the risk of developing MS increased 
(5,96). It is important to note that recollection of past events by patients can be subjective, 
especially as IM symptoms could be mistaken for a cold or flu. Nonetheless, there is 




 EBV and the immune system 
5.1.1 T lymphocyte responses against EBV 
T lymphocytes have been a major focus of research into the complex immunological 
relationship between EBV and MS. It is theorized that CD8+ T lymphocytes are defective 
in their control of proliferating EBV-infected auto-reactive B lymphocytes. A study by 
Pender completed this year confirmed that defective CD8+ T lymphocytes may be the 
reason why B lymphocytes latently infected with EBV are able to clonally expand into 
an autoreactive population in MS patients (97). Pender and colleagues had already 
demonstrated in an earlier study that a deficiency in CD8+ T lymphocytes is persistent in 
MS patients, which would explain the impaired control of infected B lymphocytes (98). 
Nevertheless, a study last year by van Nierop, et al., has revealed there is no evidence of 
intrathecal CD8+ or CD4+ T lymphocyte reactivity to MS self-antigens after the onset of 
disease and there are currently no studies on the reactivity of T lymphocytes to MS 
antigens prior to the onset of disease (99).  However, van Nierop, et al., also determined 
in another study that intrathecal CD8+ T lymphocytes of MS patients recognise lytic EBV 
proteins (100), proving a direct link between T lymphocytes and EBV. Whilst T 
lymphocytes have been prominent in research into the link between MS and EBV, B 
lymphocytes are also a major focus, as they are the carriers of EBV. 
 
5.1.2 Acute EBV infection of B lymphocytes 
EBV infection mechanisms in healthy human carriers begin with primary infection of 
circulating naive B lymphocytes in the oropharynx and the epithelial cells of the tonsils, 
as shown in Figure 5.1. EBV gains entry to the cell by the binding of the glycoprotein 
gp350 to the cell surface complement receptor 2 (CR2), the most common glycoprotein 
on its surface, as well as the aid of other glycoproteins (81). EBV replicates in the B 
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lymphocytes and causes clonal transformation. Typically, the immune system is primed 
by memory T lymphocytes to reactivate EBV-specific cytotoxic CD8+ T lymphocytes, 
which control the growth of EBV-transformed B lymphocytes, but are prevented from 
attacking EBV-infected resting B lymphocytes, enabling persistent infection (101). These 
latently infected memory B lymphocytes move to tonsil lymphoid tissue and then the 
blood and other lymphoid tissue to exist in dissemination. Subsequently, the infected 
memory B lymphocyte persistence is lifelong in the individual. During acute infection, 
when the EBV is reaching the maturation phase, it adjusts the structure of the nuclear 
membrane of immune cells to allow lytic reproduction (102). Lytic infection is 
characterized by EBV replication in the B lymphocytes and subsequent cell lysis with 
virion release. Released virions can infect more B lymphocytes and epithelial cells, 
enabling shedding of EBV in saliva and blood (101). This shedding of EBV is what 






Figure 5.1. Acute and latent EBV infection mechanisms in normal healthy individuals 
(101). The EBV virion infects B lymphocytes and epithelial cells in the oropharynx. The 
virus subsequently uses the B lymphocytes as tools of replication and causes clonal 
expansion. During lytic infection, the EBV virions burst the cell membrane, entering the 
lymph gland environment to infect more B lymphocytes and replicate again. The released 
virions can be passed on to other individuals through saliva (101). The immune response 
of T lymphocytes inhibits excessive expansion of the infected B lymphocytes however 
some EBV cells persist in memory B lymphocytes and enter latency (Image taken from 




5.1.3 Latent EBV infection of B lymphocytes 
Latent EBV will persist in the human body for the individual’s lifetime. EBV can be 
reactivated in B lymphocytes if the immune system is compromised and enter the lytic 
stage again. In rare cases, EBV can cause tumorigenesis and cancerous development such 
as Burkitt's lymphoma, nasopharyngeal carcinomas, oral leukoplakia with higher 
prevalence in low socio-economic countries (103). In the case of MS, it is theorised that 
EBV-infected memory B lymphocytes interact with APCs, such as dendritic cells, during 
latency and cause a skewed Th1 autoimmune response against the myelin sheath of the 
CNS (70). This may be how the virus is able to hide from the immune system during the 
three stages of latency, I, II and III (104). These stages are characterized by the initiation 
of mitosis of infected memory B lymphocytes and creation of a germinal centre to persist 
in and clonal expansion respectively (104).  
 
5.2 EBV gene expression 
In latency, EBV genes express proteins that can aid in the persistence of the virus within 
B lymphocytes. These include Epstein-Barr virus Nuclear Antigen 1 (EBNA-1), Epstein-
Barr virus-encoded small RNAs (EBER), Latent Membrane Protein 1 and 2 (LMP1 and 
LMP2). EBNA-1 is expressed throughout the virus lifecycle, including latency and lytic 
stages, and functions in the suppression of viral reactivation as well as the disruption of 
promyelocytic leukaemia nuclear bodies of infected cells in order to initiate the cell lysis 
cascade (105). Latency II and III phases both have the presence of LMP1 and LMP2, 
which are viral membrane proteins indirectly transactivated by EBNA-1 (94). EBNA-1 
is of major importance to the virus as in order to ensure duplication of the viral genome 
during mitosis, it attaches the viral episome to the host genomic DNA. (105). 
Additionally, EBV cannot reactivate without the essential EBNA-1 gene positively 
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affecting its own synthesis through a latently-active promotor, as shown in studies (106). 
LMP, an important component of the membrane, enables the EBV-mediated 
transformation of cells (107). The role of EBER, a highly expressed RNA with no gene 
product, is unclear, however, it has been theorized that it is involved with the oncogenic 
activity of the virus due to its ability to confer resistance to apoptosis, increase in 
tumorigenicity of the virus and induction of growth factor production (108). The constant 
latent expression of EBNA-1 and EBER make them ideal targets for quantification of 




 EBV detection 
Researchers have previously detected EBV in lytic and latent infection using various 
methods including serology testing, DNA analysis and in situ cellular studies. The link 
between MS and EBV has previously been studied due to the presence of high EBV-
specific antibody titres (50) in MS patients, as produced by B lymphocytes that have 
converted into plasmablasts. These antibodies were detected for serology by enzyme-
linked immunosorbent assay (ELISA) (50). However, B lymphocytes have been known 
to act as APCs (70) and hence it is important to determine if EBV-infected B lymphocytes 
are related to autoimmunity in EBV latency by detecting latent EBV genome copy 
numbers. There have been various methods used to detect EBV in lytic infection, either 
during acute initial infection or reactivation of the virus. Often, reactivation of the virus 
can lead to tumorigenesis of cells where tumours can develop, such as Burkitt’s 
lymphoma and nasopharyngeal carcinoma (103). For the purpose of creating an EBV-
infected cell line, single cells containing EBV have been extracted from tumours and 
expanded for analysis of EBV  in the past (109). Incidentally, methods have been 
developed to detect EBV within these cell lines where there are high copy numbers of the 
EBV genome. A commonly used technique is in situ hybridisation, which has been in use 
for EBV detection since 1996 (110). This method has successfully determined EBV 
infection in both lytic and latent states, using a large DNA probe of 14.7kb specific for 
BamHI, a fragment of the EBV genome, to detect from as little as eight EBV genomes to 
200 EBV genomes per 105 PBMCs (111). However, it is difficult to accurately quantitate 
DNA copies using this technique due to the need for manual counting, as opposed to 




Alternatively, a technique of particular note is the use of quantitative reverse-transcription 
polymerase chain reaction (qRT-PCR) for automated quantification of lytic EBV RNA 
transcripts. This method requires a standard curve to be developed using serial dilutions 
of the target to allow comparison for quantification. Though the low viral load during the 
phases of latency makes detection of EBV difficult, the constant expression of EBNA-1 
and EBER in latency can aid in detection. EBNA-1 is difficult to detect due its glycine-
alanine rich region, which cross-binds with host genomic DNA during PCR methods (69) 
Hence, a technique to eliminate the presence of genomic DNA is needed, such as qRT-
PCR, where the initial sample is RNA converted into cDNA (112). qRT-PCR has been 
used for lytic EBV quantification in multiple studies of EBV-infected cell lines (112,113), 
however, qRT-PCR has only quantitated EBV in latency in two studies (114,115), with a 
detection limit as low as 16 copies/mL of EBNA-1. Only one of these qRT-PCR studies, 
by Cocuzza and colleagues, was commenced in the context of MS and there was found 
to be no significant difference in EBNA-1 copy numbers in CSF and whole blood between 
relapsing-remitting MS and healthy controls (115). However, it was noted that the method 
of RNA extraction was not consistent with other studies (115). qRT-PCR can be used for 
detection of EBV in lytic infection, however, this technique needs to be tested further in 
latent infection. 
A recently available method of quantification is digital droplet polymerase chain reaction 
(ddPCR). Oil droplets are utilized in this technique to separate the DNA strands for 
automated quantification. ddPCR has been successfully used for EBV detection in high 
viral load samples by Vo, et al., who quantified lytic EBV in whole blood in the context 
of nasopharyngeal analysis (116), with a minimum limit of detection verified to be 9 DNA 
copies/mL. Other viruses, such as human immunodeficiency virus (HIV), were 
previously detected in latency using ddPCR, which the group compared to qPCR results 
for the same samples. Trypsteen, et al. did not find a significant difference between the 
23 
 
two methods (117). ddPCR has so far not been used to quantify latent EBV when very 
low copy numbers are expected. 
A technique called flow cytometry couples with fluorescent in situ hybridisation (Flow-
FISH) was used to detect EBV-transformed cell lines from Burkitt’s lymphoma tissue 
and peripheral blood from patients with lymphoproliferative disease. One study, by 
Kimura and colleagues, used a peptide nucleic acid (PNA) probe specific for EBER for 
EBV identification by flow cytometry for determination of EBV in lymphoproliferative 
diseases (118). This assay successfully determined lymphocyte infection with lytic EBV 
(118), however, the technique has not yet been used for latent EBV PBMC infection 
analysis. A second study used the same EBER PNA probe for characterization of EBV-
transformed cell lines Raji, Daudi and HS-Sultan to determine the suitability of this probe 
for flow cytometry analysis (119). The probe was concluded to be appropriate for the 




 B lymphocytes and MS 
7.1 B lymphocytes in the central nervous system 
B lymphocytes have previously been considered secondary to T lymphocytes in terms of 
finding a clinical target for MS. While evidence demonstrates that T lymphocytes 
recognise self-antigens due to EBV in MS, there is data to indicate that B lymphocytes 
produce antibodies specific for self-antigen (74). A number of studies give evidence for 
the changes of B lymphocytes behaviour during MS disease, such as detectable increased 
presence in the CNS in MS, however, this is heavily disputed (120,121,1). 
The presence of B lymphocyte follicle-like structures in the subarachnoid space of the 
CNS in MS have demonstrated increasing demyelination in one study (121). Krumbholz 
and colleagues discovered that in MS, an environment can be created in these follicle 
structures that enable the further development of B lymphocytes, as determined by the 
presence of B lymphocyte-activated factor of the TNF family factor, a proliferation-
inducing ligand and plasma cell survival factor (122). This increases B lymphocyte 
expansion (122). This may be evidence for an environment in the CNS of MS patients 
that allows the expansion of B lymphocytes. 
EBV-infected B lymphocytes were used as APCs in a study and there was confirmed to 
be significant T lymphocyte reactivity in the CNS in the presence of lytic EBV proteins 
(100). This is a result of dysregulation of B lymphocytes by EBV, which can be discerned 
in white lesions in the CNS of MS patients at all stages of the disease according to one 
study (88). By analysis of post-mortem MS brain tissue in a 2010 study, there appeared 
to be EBV deposits with lesions comprising CD27+ T lymphocytes along with the 
presence of survival and maturation signals for B lymphocytes (3).  Possibly pathogenic 
memory B lymphocytes have been identified in MS, including CD22, CD24, CD25, 
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CD27, CD49d, CD83, CD180, CD38low, HLA-DR, CCR2 CCR6 (120), however, there is 
yet to be studies into the relationship between these pathogenic B lymphocytes and EBV. 
More recently, the levels of EBNA-1 antibodies have been proven to be higher in the 
serum (69) of MS patients than controls and CSF or both, hence making peripheral blood 
an excellent source for sampling levels in MS patients as opposed to CSF via the lumbar 
puncture, which is a current diagnostic measure (123). Peripheral blood would be a 




 Study rationale 
The complex relationship between EBV, MS and the immune system, particularly B 
lymphocytes, requires further focussed research. EBV has been implicated in MS, as 
evident in high antibody titres specific for EBV in peripheral blood in MS patients 
compared to healthy controls (50). Further evidence for this association is the high EBV 
specific oligoclonal bands in the CSF of MS patients, not found in controls (7). 
Additionally, the linkage between MS and EBV infection is further supported by the 
increased risk of MS disease when individuals had symptomatic EBV infection and 
presented with infectious mononucleosis. Moreover, previous studies have linked the 
significance of EBV as a key trigger for MS in conjunction with other risk factors such 
as Vitamin D and HLA loci and how B lymphocytes are involved in EBV in humoral 
immune response.  
The role of  T lymphocytes was initially always the main focus of MS research (69) into 
the relationship between EBV and MS, however, the role of EBV-infected B lymphocytes 
has quickly become of interest due to their role as APCs (70). More recently, the 
significance of B lymphocytes has become apparent in the results of B lymphocyte 
depletion therapy in MS patients as the absence of B lymphocytes significantly reduced 
MS remission and symptoms (45,46). Whilst EBV is known to reside within B 
lymphocytes in latency, it is unknown if the amount of EBV within different B 
lymphocyte subsets varies between MS patients and healthy controls and if these infected 
cells are more likely to develop into plasma cells, produce cross-reactivity producing 
antibodies or serve as APCs.  
The detection of EBV in latency has proven difficult due to poor sensitivity for low viral 
genome copy numbers. However, the technique of FISH has been used with flow 
cytometry to detect EBER expressed by EBV in latency for EBV detection method 
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development within infected cells in a single study of infected peripheral lymphocyte 
subtypes, but not in MS (118). This technique does not allow the accurate quantification 
of EBV due to the need for manual counting. However, some automated techniques, such 
as ddPCR and qPCR, have been used in single studies to quantitate the latently expressed 
EBNA-1 at low levels of 10 copies/mL and 16 copies/mL respectively (116,124). These 
techniques are yet to be replicated and they have not yet been used for EBV in the context 
of MS. 
Once EBV can be reliably detected in latency, the functional properties of EBV-infected 
B lymphocytes in MS can be defined. This will contribute to research into new biomarkers 
in the disease and ultimately lead to improvement of the quality of life for MS patients, 




 Hypothesis and aims 
In this study, a method for EBV quantification in B lymphocytes in MS patients and 
healthy controls will be used to determine which B lymphocytes are latently EBV infected 
and if there is a significant difference in EBV genome copy numbers between different B 
lymphocytes subsets in MS patients in comparison to healthy controls. qPCR and ddPCR 
have been shown in other studies to be highly sensitive quantitative methods. In this 
project, they will be utilized to detect EBNA-1, a latently expressed gene. To determine 
the ratio between the different B lymphocyte subsets, B lymphocytes will be isolated by 
negative selection. In a third quantification method, Flow-FISH will be used to target 
EBER, a highly expressed EBV RNA in latency, to identify EBER positive B lymphocyte 
subsets in flow cytometry. These techniques are proposed to allow the quantification of 
EBV at very low levels in latency in MS patients and healthy controls.  
 
We hypothesize that i) it is important to gain knowledge about EBV copy numbers in B 
lymphocyte subsets and that ii) the comparison between ddPCR, qPCR and flow-FISH 
will inform about the best suitable method for sensitive and specific EBV quantification 
in B lymphocytes. iii) Using the combination of sensitive EBV quantification will 
elucidate EBV copy numbers in B lymphocytes subsets. By defining specific EBV-
containing B lymphocyte subsets, this research may provide valuable guidelines for MS 
therapy by targeting B lymphocyte depletion therapy more specifically for a subset of B 
lymphocytes only, limiting side effects and improving quality of life; and prove useful as 
a biomarker if results show different quantities of EBV in B lymphocytes between MS 






10.1 List of kits 
Kit Use Manufacturer 
RNeasy Plus RNA Extraction Kit RNA extraction QIAGEN, AU 
ddPCR EvaGreen Kit ddPCR analysis Bio-Rad, AU 
qPCR EBV ASR Probe/Primer Kit qPCR analysis QIAGEN, US 




Stem Cell Technologies, 
AU 
 
10.2 List of reagents 
Reagent                                                                               Manufacturer 




10% dimethyl sulfoxide (DMSO) Bovogen, AU 
Fetal Calf Serum (FCS) Bovogen, AU 
Phosphate Buffered Saline (PBS) Bovogen, AU 
Vi-Cell Lysis Buffer Invitrogen, AU 
RNA extraction 
β-Mercaptoethanol Invitrogen, AU 
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Ethanol Absolute AJAX, AU 
DNase I QIAGEN, AU 
DNase Buffer QIAGEN, AU 
RNase OUT Invitrogen, AU 
HLA-C PCR 
TDMH-B Buffer Sigma-Aldrich, AU 
GoTaq Polymerase Enzyme Promega, AU 
Agarose gel electrophoresis 
UltraPure Agarose Powder Invitrogen, AU 
UltraPure Ethidium Bromide Invitrogen, AU 
TAE Sigma-Aldrich, AU 
cDNA reverse transcription 
5x First Round Buffer Invitrogen, AU 
10mM dNTPs Invitrogen, AU 
DTT Invitrogen, AU 
RNase OUT Invitrogen, AU 
SuperScript III Reverse Transcriptase Invitrogen, AU 




iTaq Universal Probes Supermix Bio-Rad, AU 
B lymphocyte enrichment 
PBS Bovogen, AU 
EDTA Sigma-Aldrich, AU 
Flow-FISH analysis 
Glacial Acetic Acid Sigma-Aldrich, AU 
Paraformaldehyde Sigma-Aldrich, AU 
Tween 20 Sigma-Aldrich, AU 
Sodium Chloride Sigma-Aldrich, AU 
Disodium EDTA Sigma-Aldrich, AU 
Tris-Hydrochloric Acid Sigma-Aldrich, AU 
Formamide Sigma-Aldrich, AU 
Y5200 EBER PNA Probe DAKO, US 
10.3 List of antibodies for flow-FISH analysis 
Antibody Manufacturer 
BD Pharmingen Mouse Anti-Human CD19 PE Antibody BD Biosciences, AU 
BD Horizon Mouse Anti-Human CD24 PE-CF594 Antibody BD Biosciences, AU 
BD Horizon Mouse Anti-Human IgD Pe-Cy7 Antibody BD Biosciences, AU 
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BD Horizon Mouse Anti-Human CD20 APC-H7 Antibody BD Biosciences, AU 
BD Horizon Mouse Anti-Human CD38 BV421 Antibody BD Biosciences, AU 
 
10.4 List of primers 
Primer Target Use Manufacturer 
EBV forward/reverse 
primers 
97bp EBNA-1 qPCR QIAGEN, US 






















ddPCR  Integrated DNA 
Technologies, AU 




ddPCR Integrated DNA 
Technologies, AU 
*The ddPCR primers were developed by Dr Monika Tschochner, Institute for 




 Methods  
11.1 Collection and processing of healthy control blood samples 
38 peripheral blood samples were collected from healthy control patients from the 
Australian Red Cross and Murdoch University Clinic using vacutainer tubes with EDTA. 
Blood was diluted with RPMI, then overlayed on Ficoll and centrifuged for separation of 
peripheral blood monocytes (PBMCs). PBMCs were frozen at 10 million cells in 800µL 
with 10% dimethyl sulfoxide (DMSO) in fetal calf serum (FCS) in liquid nitrogen at -
80ᵒC for future testing. When needed, cells were thawed and washed twice with PBS by 
centrifugation and rested overnight in an incubator for 12-18 hours in 5mL of R10 at 37ᵒC 
at 5% CO2. 
After resting, the PBMCs were resuspended in 10mL PBS and counted in the Vi-Cell 
counter (Invitrogen, AU) using 540µL of cell lysis buffer and 60µL of sample. PBMCs 
were then centrifuged again and resuspended in the required amount of media or buffer 
as per protocol for either flow cytometry, qPCR or ddPCR experiments.  
 
11.2 Extraction of RNA from PBMCs for quantification 
RNA was extracted using the commercial RNeasy Plus kit (QIAGEN, AU). RNA samples 
were kept on ice to reduce RNase activity. RNA extraction was performed according to 
manufacturer’s instructions but as a slight variation, genomic DNA was digested twice 
with DNase I to reduce non-specific amplification. Briefly, this involved the preparation 
of Buffer RLT Plus by adding 20µL β-mercaptoethanol (β-ME). To disrupt the pelleted 
cells, Buffer RLT plus and 70% ethanol was added to the sample. The sample was added 
to the RNeasy spin column membrane in a collection tube and centrifuged. Buffer RW1 
was added to the spin column and again centrifuged. The flow-through was discarded but 
the collection tube and spin column were retained. 100µL of 1:10 DNase I in buffer was 
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added to each sample. This was incubated with the sample in the spin column at room 
temperature for 30 minutes, instead of the 15 minutes recommended by the manufacturer. 
Buffer RW1 was again added and centrifuged. This was repeated with Buffer RPE. This 
wash step was repeated once more with centrifugation for 2 minutes. The spin column 
was placed into a fresh collection tube.  
To enable elution of the purified RNA, 30µL of RNase-free water was added to the 
column membrane and the sample was eluted into the collection tube after centrifugation. 
The RNA was stored at aliquots of 10µL at -80ᵒC with 1µL of RNaseOUT to reduce 
RNase activity. Nucleic acid concentration from each sample was analysed after 
extraction by spectrophotometry using Nanodrop. Each RNA sample was gel 
electrophoresed with 1µL per sample on a 1% agarose gel stained with ethidium bromide 
to confirm extraction. The gel was electrophoresed for 30 minutes at 110 volts. 
 
11.3 Use of HLA-C PCR for confirmation of RNA purity 
To determine if there is a significant amount of DNA present in the RNA sample after 
extraction, an in-house HLA-C PCR was performed. The primers (Integrated DNA 
Technologies Inc) were designed to amplify both DNA and RNA but would result in 
different lengths of 3Kbp and 1Kbp amplicons, respectively. PCR conditions are shown 








96ᵒC 6 minutes 
96ᵒC 30 seconds 
62ᵒC 30 seconds 
72ᵒC 2 minutes 
72ᵒC 10 minutes 
4ᵒC Forever 
 
Table 11.1 Thermocycling conditions for the HLA-C PCR. The PCR allows for 
amplification of DNA and RNA in samples resulting in different fragment sizes of 3Kbp 
and 1Kbp, respectively.  
 
11.4 cDNA conversion of RNA 
RNA was reverse-transcribed into complementary DNA (cDNA) using oligo dT, which 
are short sequences of deoxy-thymidine nucleotides that bind to the poly-A tail of the 
RNA and result in a free 3’ end. This 3’ end is extended by the enzyme reverse 
transcriptase. First, 10µL of each RNA sample were thawed and put on ice where 1µL of 
oligo dT was added to each sample. A negative control was substituted with 10µL water 
instead of RNA template. This mix was incubated in a thermocycler for 5 minutes at 65ᵒC 
and then cooled to 4ᵒC for at least 60 seconds on ice.  
Repeat for 35 cycles 
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The mastermix for the reverse transcription was prepared with 4µL of 5x First Round 
Buffer (Invitrogen, AU), 1µL of 10mM dNTPs, 1µL 0.5mM DTT (Invitrogen, AU), 
0.5µL RNase OUT (Invitrogen, AU) and 0.5µL CSL water. This mix was vortexed and 
8µL of the mix was added to each sample. 0.5 µL of Superscript III Reverse Transcriptase 
(Invitrogen, AU) was added to each sample except the negative control for the enzyme. 
This mixture was vortexed and then centrifuged for 30 seconds to ensure liquid was at 
the bottom of the tube. The thermocycler settings for the conversion was 42ᵒC for 60 
minutes, 95ᵒC for 3 minutes and then 4ᵒC forever. cDNA was stored at -20ᵒC and freeze-
thawing avoided. The maximum number of thawing times for cDNA for downstream 
assays was set to two times. 
 
11.5 Protocol for digital droplet PCR (ddPCR) 
The EBNA-1 cDNA was quantified using a digital droplet PCR (ddPCR) protocol with 
an oil droplet generator and reader (Bio-Rad, AU). The ddPCR EvaGreen dye (Bio-Rad) 
mastermix was made up with 12.5µL ddPCR EvaGreen Supermix, 0.1µL forward primer, 
0.1µL reverse primer and 9.8µL CSL water to make a total of 22.5µL mastermix per 
sample. 2.5µL of cDNA sample was added to this mastermix. The EvaGreen dye binds 
to amplifying DNA and fluoresces.  
The primers used were specific for the region of EBNA-1 between positions 109111 and 
109951. The positive control used was Daudi, an EBV-transformed cell population from 
which highly concentrated EBV DNA had been extracted.  Two negative controls were 
used including a negative enzyme control and negative sample control. The 20µL of the 
sample and mastermix was automatically pipetted into the DG8 cartridge (Bio-Rad) as 
per the ddPCR droplet generator protocol. 70µL of the EvaGreen droplet oil was also 
automatically pipetted to the DG8 cartridge within separate wells. A gasket was then 
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attached across the DG8 cartridge and the cartridge was placed in the QX200 droplet 
generator. The QX200 was expected to generate ~20,000 droplets/sample in 2.5 minutes 
for 8 samples. The droplets formed were transferred into a 96 well opaque plate with full 
skirt slowly using an automated pipette, to avoid disturbance of the droplets or formation 
of air bubbles. The plate was heat sealed at 170ᵒC with BioRad PX1 PCR plate sealer and 
pierceable foil heat seal. The thermocycling program was 95ᵒC for 5 minutes then 40 
cycles of 95ᵒC for 30 seconds and 60ᵒC for 1 minute, then 4ᵒC for 5 minutes, 90ᵒC for 5 
minutes then 10ᵒC forever. 
The amplified product was analysed using Bio-Rad ddPCR reader and Quantisoft analysis 
software (Bio-Rad) which gave the concentration of the sample in DNA copies/µL. 
Fluorescence of the EvaGreen dye was measured and if it reached the cut-off threshold it 
was defined as positive, otherwise samples below the threshold were considered negative.  
The concentration of the samples was calculated by using the proportion of positive and 
negative droplets and Poisson statistics. The leftover amplified product was alongside a 
1Kbp Plus DNA ladder on a 1% agarose gel stained with ethidium bromide and visualised 
to determine amplicon length. ddPCR amplified products were analysed by Sanger 
sequencing. 
 
11.6 Protocol for quantitative PCR (qPCR) 
11.6.1 EBNA-1 standard development for qPCR 
The standard used for qPCR was clonally expanded in a plasmid and was a section of 
EBNA-1. The plasmid was donated by Anuradha Sooda (IIID) and was isolated by length 
by electrophoresis on a 1% agarose gel to confirm amplification. The plasmid was 
restriction digested and the terminal ends of the gene were flanked by M13 primer targets 
to enable isolation of EBNA-1 by amplification with generic primers. The amplified 
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product was electrophoresed in agarose gel once more and pooled to enable increased 
concentration of the product. The product was cut from the gel and purified using spin 
columns. The purified standard was analysed in triplicate by Nanodrop 
spectrophotometry for concentration and sequenced using next-generation sequencing as 
per method used previously by Abha Chopra, et al. (125). The number of DNA copies 
present in the product was determined by calculation using the results of the Nanodrop 
analysis.  
The standard was serially diluted by 1:10 in Milli-Q water. The serial dilutions, when 
amplified in qPCR, enabled comparison for quantification of EBNA-1 in samples. Serial 
dilutions of the standard were tested in all qPCR assays. 
A standard curve was generated by plotting log[known EBNA-1 DNA standard copy 
number] against quantification cycle (Cq) value after qPCR amplification. The Cq value 
was based on fluorescence of the probe binding to exponentially amplified DNA when 
crossing the threshold. The slope of the standard curve determined DNA copy number of 
healthy control samples per 100,000 PBMCs by comparison to initial PBMC counts. 
 
11.6.2 qPCR reaction 
The qPCR reaction was set up using a master mix of 200nM forward and reverse primers 
(QIAGEN US) and 170nM EBV probe (QIAGEN US) with iTaq universal probe 
supermix 2x (Bio-Rad AU). 2µL of cDNA sample was added to this mastermix for each 
healthy control and these samples were assayed in triplicate. 
The thermocycling conditions of the qPCR were 95ᵒC for 30 seconds for polymerase 
activation and DNA denaturation, then 60 cycles of denaturation at 95ᵒC for 5 seconds 
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and annealing/extension and plate read at 60ᵒC for 30 seconds. The fluorescence was 
analysed by Bio-Rad CFX Manager software (Bio-Rad). 
11.6.3 qPCR calculations 
The calculation of EBNA-1 DNA copy number was derived from the Cq values of healthy 
control samples relative to the Cq values of the standard curve. Using the known standard 
DNA copies against the standard curve Cq values, the healthy control DNA copy number 
was calculated. The slope of the standard curve was given using the equation:  
slope=(x2-x1)-(y2-y1) 
The number of cycles of standard (Cq value) and log10[standard DNA copy number] were 
substituted into the equation. The slope value was used to substitute with Cq value for the 
samples, giving log10[sample DNA copy number]. The inverse log of the healthy control 
DNA copy number was calculated, and this value was compared to the original cell count 
taken prior to RNA extraction. To enable relative comparison between samples, the 
quantity of DNA was given as DNA copy number/100,000 PBMCs. 
Amplification efficiency of the qPCR primers and probe were analysed to determine if 
the 97bp EBNA-1 product was doubled with each amplification cycle. The ideal 
efficiency would be 100%, with a difference of 3.3 amplification cycles (or Cq value) 
between 10-fold dilutions of the standard. Amplification efficiency was calculated using 
a formula from Bio-Rad (126) and the threshold cycle was plotted against the log10[DNA 
copy number] to the data with a regression line. The amplification efficiency was 
calculated with the following formula: 





11.7 Enrichment of B lymphocytes 
Copy numbers in EBV latency were expected to be minimal. To enable successful 
detection, B lymphocytes were enriched for flow-FISH detection of EBER, using a 
negative selection B lymphocyte isolation kit from Stem Cell Technologies. PBMCs of 
healthy controls were resuspended to a concentration of 5 x 10^7 cells/mL (0.25 to 2mL) 
in the recommended medium of PBS containing 2% FCS and 1mM EDTA, which is free 
from calcium and magnesium ions as per the isolation kit requirements. 
The sample was added to a 5mL polystyrene tube and the Cocktail Enhancer (Stem Cell 
Technologies, AU), which enhances the effects of B lymphocyte enrichment, was added 
at 50µL/sample. The same amount of Isolation Cocktail (Stem Cell Technologies, AU), 
which is a combination of monoclonal antibodies in PBS, was also then added, mixed and 
incubated for 5 minutes at room temperature. 
The RapidSpheres (Stem Cell Technologies, AU), which are magnetic particles 
suspended in water, were vortexed for 30 seconds and added to the samples at 50µL/mL 
sample and mixed by vortexing. The PBS medium was added to make the sample volume 
up to 2.5mL and the tube was placed into the EasySep magnet with the lid removed. This 
mix was incubated for 3 minutes at room temperature. After incubation, the enriched B 
lymphocytes were poured out of the tube in the magnet into a 5mL fresh tube by inverting 
for 2-3 seconds without shaking. This new tube replaced the previous one in the magnet 
for a second separation for 1 minute at room temperature. Once more, the tube was 
inverted whilst still in the magnet to release the enriched B lymphocytes into another fresh 




11.8 Protocol for flow cytometry coupled with fluorescent in situ hybridisation 
(flow-FISH) 
PBMCs only have a very small fraction of B lymphocytes and approximately only 1% of 
those cells are infected with EBV in latency (70). Fluorescent in situ hybridization 
coupled with flow cytometry (flow-FISH) gates lymphocyte subsets by surface markers 
to allow identification of EBV-infected lymphocytes.  
Surface antibody incubation and intracellular staining procedure for detection of EBV-
positive lymphocytes with an EBER-specific peptide nucleic acid (PNA) probe (DAKO) 
and flow cytometry. The FITC-labelled probe is specific for EBER RNA. All efforts were 
made to avoid ribonuclease contamination by using aseptic technique and sterilized 
equipment. 
After overnight resting of PBMCs, cell count and then B lymphocyte enrichment, the 
cells were incubated with antibodies directed against B lymphocyte surface markers (CD) 
CD19+, IgD+, CD20+, CD38+ and CD27+. Using different fluorochrome-coupled 
antibodies allowed for differentiation between different B lymphocyte subsets in 
subsequent flow cytometry.  
The surface antibody marker panel included anti-CD19, anti-CD24, anti-IgD, anti-CD20, 
anti-CD38 and anti-CD27, as shown in Table 11.2. Antibodies were incubated with cells 
were incubated in the dark at 4ᵒC. Cells were then washed in a buffer containing 1x PBS 
and 2% FCS and centrifuged at 300 x g for 5 minutes. The supernatant was aspirated and 
discarded. The cell pellet was used for subsequent fixation and permeabilization for 






Antibody/Probe Fluorophore Detector Volume 
(µL) 




EBER FITC FL1 7 552 410 
CD19 PE FL2 7 500 480 
CD24 PE-CF594 FL3 4 436 422 
IgD Pe-Cy7 FL5 4 832 676 
CD20 APC-H7 FL8 3 600 577 
CD38 BV421 FL9 5 461 368 
CD27 BV510 FL10 4 467 343 
Table 11.2 List and volumes of surface antibodies used for flow-FISH and the Kaluza 
(Beckman Coulter) flow cytometer voltage settings used for healthy control B 
lymphocytes and LCLs. Laser detector channels and fluorophores are included. 
 
Surface marker-stained cells were fixed for 20 minutes at room temperature in a mixture 
of 4% v/v paraformaldehyde with PBS. To make the fixation mixture, 2g of polymerized 
paraformaldehyde was added to 50mL PBS and warmed to 60ᵒC whilst pipetting 1M 
NaOH dropwise (approximately 2mL) to the mixture until the paraformaldehyde 
dissolved. The solution was returned to a pH of 6.9 by the addition of HCl dropwise 
(approximately 0.5mL) whilst using a calibrated pH meter (Beckman Coulter). After 
fixation, the cells were washed twice with PBS/FCS buffer and stored at 4ᵒC in PBS 
before permeabilization for intracellular staining and tested in flow cytometry within 3 
days. 
Post-incubation period, the cells were then counted once more and for each sample a total 
of approximately 5-10 x 105 cells were used. These cells were centrifuged at 3500 x g for 
5 minutes and then the supernatant was discarded. Permeabilization of the cells prior to 
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hybridization occurred for 10 minutes in 50 µL 0.5% Tween 20 in PBS at room 
temperature.  
The formamide and buffer concentrations were approximately the same as the 
hybridization solution, i.e. 31.25mM NaCl, 6.25mM Na2EDTA, 62.5mM Tris-HCl at pH 
7.5 and 37.5% formamide. RNase-free water was used to make this mixture.  
The EBER probe was initially added at 50µL (DAKO, US) of probe and hybridization 
solution included with the probe (10% (w/v) dextran sulfate, 10 mM NaCl, 30% (v/v) 
formamide, 0.1% (w/v) sodium pyrophosphate, 0.2% (w/v) polyvinylpyrrolidone, 0.2% 
(w/v) Ficoll, 5 mM Na2EDTA, 50 mM Tris-HCl pH 7.5)). In subsequent testing, the probe 
was added at 100µL. 
The EBER probe was incubated with the B lymphocytes for 60 minutes at 56ᵒC and then 
1 mL of 0.5% Tween 20/PBS was added and incubated again for 10 minutes at 56ᵒC. 
After incubation, the cells were then centrifuged at 3500 x g for 5 minutes and the 
supernatant was aspirated and discarded. Once more, the cells were incubated for 30 
minutes at 56ᵒC with 1 mL of 0.5% Tween 20/PBS and then centrifuged at 3500 x g for 
5 minutes. The supernatant was once more discarded. The B lymphocytes were 
resuspended in 0.5% Tween/PBS at room temperature and analyzed by the Gallios flow 
cytometer (Beckman Coulter).  
 
11.8.1 Flow cytometry analysis using Kaluza (Beckman Coulter) 
Initially, the flow cytometry panel had to be optimized using single-stained cells with one 
antibody only, one negative control containing unstained cells, and one containing the 
EBER probe. The negative control tube was to ensure there was no background 
fluorescence. Following this procedure, optimal voltage and compensations could be 
established, as shown in Table 11.3. Compensation was required to correct for 
overlapping emission spectra of antibodies. 
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The results of this optimization gave flow cytometer voltages, as shown in Table 15.2 and 
compensations used are in Table 11.3. Kaluza software (Beckman Coulter) was used to 
visualize event count and scatter as well as allow compensation and voltage adjustments. 
The compensations used for the flow cytometry analysis were determined by using single 
stains of antibodies and probe and the Y-axis median value, which must be equal between 
positive and negative cell populations. The subsequent compensation values for both 






















 0 0 0 0 0 0 
FL2 (PE) 30.60  6.90 0 0 0 0 
FL3 (PE-
CF594) 
29.00 20.20  0 0 0 0 
FL5 (Pe-
Cy7) 
55.00 0 21.18  0 0 0 
FL8 
(APC-H7) 
2.83 0 0 0  0 0 
FL9 
(BV421) 
57.64 0 0 0 0  8.87 
FL10 
(BV510) 
80.79 4.93 0 0 0 3.94  
 
Table 11.3 Healthy control compensations used for each laser channel with fluorophores. 
Compensations were adjusted in Kaluza for flow cytometry analysis of healthy control 
























 14.78 21.54 2.00 0.75 1.30 0.00 
FL2 (PE) 28.08  52.75 2.00 2.50 0.99 0.00 
FL3 (PE-
CF594) 
5.42 20.20  7.00 2.95 0.99 0.00 
FL5 (Pe-
Cy7) 
0.00 0.00 16.00  5.90 0.20 0.00 
FL8 
(APC-H7) 
0.00 0.00 13.41 9.50  0.00 0.00 
FL9 
(BV421) 
0.00 0.00 21.60 4.00 2.50  15.27 
FL10 
(BV510) 
2.48 4.93 21.75 2.50 0.12 2.50  
Table 11.4 Lymphoblastoid cell line (LCL) compensations used for each laser channel 
with fluorophores. Compensations were adjusted in Kaluza for flow cytometry analysis 
of LCL to allow accurate quantification of stained cells. 
 
11.8.2 Gating strategy for B lymphocyte subsets and EBER probe 
As shown in Figure 11.1, B lymphocyte subsets and EBER probe were distinguished by 
gating of the light scatter profiles from the cell populations tested by flow cytometry. The 
events detected by the flow cytometer were counted over time and these were gated as 
“Events” as shown in Figure 11.1(a). The start and end of the sample detection were not 
included to avoid cell debris. The forward and side scatterplot was gated on these 
“Events” and the cell population shown in Figure 11.1(b) was gated for lymphocyte 
populations to avoid non-lymphocytes. The forward scatterplot in Figure 11.1(c) 
compared the width of the cells with the area of the cells and enabled separation of 
doubled-up cells for single cells, or “singlets”, when gated against the lymphocytes 
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population in Figure 11.1(b). The positive EBER events, shown as “EBER Positive” in 
Figure 11.1(d), were gated for by a histogram count of singlet events in the FITC channel 
when compared to a negative EBER population. These EBER positive events were gated 
on by subsequent B cell subset scatterplots, as shown in Figure 11.1(e-i). Plasmablasts, 
which are C19+/CD20-, were gated by the lower right quadrant of the scatterplot between 
channels for CD20/APC-H7 and CD19/PE. In the scatterplot for channels CD27/BV510 
and IgD/Pe-Cy7, switched memory B lymphocytes (CD27+/IgD-), non-switched 
memory B lymphocytes (CD27+/IgD+), and naïve B lymphocytes (CD27-/IgD+) were 
gated by the upper left, upper right, and lower right quadrants, respectively. Immature 
transitional B lymphocytes (CD38++/CD24++) were gated by the far upper right quadrant 
of the scatterplot for channels CD24/Pe-Cy7 and CD38/BV421. Mature memory B 
lymphocytes (CD27+/CD19+) were gated by the upper right quadrant of the scatterplot 







Figure 11.1. Gating strategy for B lymphocyte subsets. a) Initially, the histogram plot of 
flow events is gated to exclude the initial and final events from analysis and these are 
gated upon in b) in a scatterplot of forward scatter and side scatter where the lymphocyte 
population is gated, and the cell debris is excluded. c) Doublet cells were discriminated 
against by gating the lymphocytes in a forward scatterplot of cell width vs cell area. These 
‘singlets’ are gated on by d) histogram plot of EBER/FITC events, with EBER positive 
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events gated on by the remaining B lymphocyte subset gates. e) CD38++/CD27++ EBER 
positive events were gated for by scatterplot of fluorophores BV510 and BV421. f) 
CD27+/CD20- EBER positive plasmablasts were gated for by scatterplot of fluorophores 
PE and APC-H7. g) EBER positive class-switched memory B lymphocytes (CD27+/IgD-
), non-class switched memory B lymphocytes (CD27+/IgD+) and naïve B lymphocytes 
(CD27-/IgD+) were gated for by scatterplot of fluorophores BV510 and Pe-Cy7. h) EBER 
positive immature transitional B lymphocytes (CD24++/CD38++) were gated for by 
scatterplot of fluorophores of PE-Cf594 and BV421 and i) EBER positive mature memory 






12.1 RNA extraction results (Nanodrop and gel electrophoresis) 
After RNA extraction, the product was measured using Nanodrop spectrophotometry. 
The mean RNA concentration of 38 samples was 31.02 ng/mL, ranging from 8.3 ng/mL 
to 87.76 ng/mL.  
For additional confirmation of product, purity and state of degradation, extracted RNA 
was also visualised after 1% agarose gel electrophoresis and compared to a 1Kbp Plus 
DNA molecular weight ladder. The RNA displayed fragments of multiple lengths ranging 
from 500bp to 2000bp, as observed in Figure 12.1. Of note, only two RNA samples are 
presented here. As spectral absorbance of DNA and RNA samples is different, the ratio 
of absorbance at 260nm and 280nm was determined. Nanodrop spectrophotometry 
determined and resulted in a mean ratio of 1.70 in samples, ranging from 1.36 to 2.13. 
 
 
Figure 12.1. RNA extraction products from 
two healthy controls in 1% agarose gel. Lane 
1 and 2 are healthy control RNA with 
multiple fragments at varying lengths 




12.2 HLA-C PCR results 
HLA-C PCR was performed to test if RNA extracted samples still contained partial 
genomic DNA. The agarose gel electrophoresis of the HLA-C PCR products exhibited 
bands of expected band lengths for RNA and DNA of 1Kbp and 3kbp respectively for 
most samples (Figure 12.2). Of note, only 20 of the 38 samples were visually tested. The 
correct RNA fragment was visible in all samples except for Sample 1 and was absent in 
the negative controls. Similarly, DNA bands were present in all samples, but not the 
negative controls and Sample 1, despite performing DNAse treatment on extracted 
samples twice. In addition to the DNA fragment of 3Kbp, samples contained shorter 
fragments. While bands were absent in all negative controls, band intensity varied 
considerably between samples.   
 
Figure 12.2. Results of HLA-C PCR gel electrophoresis on a 1% agarose gel. Lanes 1 to 
20 represent healthy control samples. 1Kbp fragments represent the successful RNA, 
3Kbp represent genomic DNA amplification. Of note, additional shorter bands were 
visible in all samples except for the negative controls. 
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12.3 Quantification of EBNA-1 by digital droplet PCR (ddPCR)  
12.3.1 Optimisation of ddPCR 
EvaGreen ddPCR uses a fluorescent dye specific for amplified DNA and oil that separates 
DNA, resulting in one copy of DNA in each oil droplet. Importantly, this assay detects 
the presence of any type of amplified DNA and is therefore reliant on the specificity of 
the EBNA-1 primers to ensure only the target EBNA-1 DNA was amplified.  
Dilutions of 1:100, 1:1000 and 1:10,000 of the lymphoblastoid cell line Daudi were used 
as a positive control. The 1:1000 and 1:10,000 dilutions were successfully quantified by 
the ddPCR reader with 1428 copies/mL and 282 copies/mL, respectively. The more 
concentrated Daudi dilution of 1:100 did not lie within the measuring range of the 
machine and was out of range at the upper end. ddPCR products were additionally 
visualised by agarose gel electrophoresis to test for amplicon length and therefore primer 
specificity. As observed in Figure 12.3, the expected fragment of 850bp was clearly 
visible in all three dilutions of the positive control. However, additional fragments of 
shorter length were also present (~100bp, ~250bp, ~380bp). In the next step, the smaller 
DNA fragments were purified separately from the agarose gel and sequenced to test if 
they represent EBV or unspecific genomic DNA amplification. Sequencing results with 




Figure 12.3. Post-ddPCR amplicons of two healthy controls, two LCLs and three positive 
control Daudi dilutions from 1:100 to 1:10,000 on a 1% agarose gel. Lanes 1 and 2 are 
healthy controls and lanes 3 and 4 are LCLs. None of these samples were amplified, as 
the only bands present are from primer dimers. The target fragment length of this PCR 
was 850bp, however, amplicons at multiple lengths, including 850bp, were visualised for 
the Daudi dilutions. These non-target fragments were present at lengths ~100bp, ~250bp 
and ~380bp at decreasing intensity with decreasing dilution. 
The primers used in this method were previously developed by Dr. Monika Tschochner 
for use in nested PCR for amplification of part of the EBNA-1 gene from DNA templates 
(69). The high homology of EBNA-1 to genomic DNA has previously been reported in 
many studies (8–10). Therefore, to reduce non-specific amplification due to EBNA-1 
homology with genomic DNA, as shown in the Daudi results, it was speculated that this 
could be reduced by starting with an RNA template rather than a DNA template. 
In the first experiment, two healthy control samples and two LCL samples were tested 
and analysed by ddPCR. Of the two healthy control samples tested, neither were detected 
and no fragments post-amplification were visualised on a 1% agarose gel (Figure 12.3). 
One of the two LCL samples were quantified by the ddPCR reader in parallel to the 
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healthy controls, and were measured to contain 2158 DNA copies/mL detected. However, 
this LCL sample did not present any fragments when visualised by agarose gel 
electrophoresis. It was later determined that the ddPCR oil used was expired as confirmed 
by laboratory technicians. However, this method was not repeated with fresh ddPCR oil 
and healthy controls samples as the sequencing results of the Daudi positive control 
fragments confirmed the ddPCR reader to be quantifying non-EBNA-1 DNA. As a result, 
this method was not tested on further samples due to amplification of multiple non-
specific fragments. 
 
12.4 Quantification of EBNA-1 by quantitative PCR (qPCR) 
12.4.1 qPCR standard development 
A standard of known EBNA-1 DNA copies was required to calculate EBV copies of 
unknown samples. To obtain a standard for qPCR, a purified EBV plasmid was used that 
spanned positions 389bp to 641bp of EBNA-1. A PCR was performed to amplify part of 
the EBV plasmid and sequenced. This sequence was confirmed to match N terminal 
EBNA-1 and is given in Table 12.1. The amplified PCR product EBNA-1 was measured 
using spectrophotometry (Nanodrop) in triplicate, with results 38.07 ng/µL, 43.52 ng/µL 
and 25.81 ng/µL. The mean concentration of the EBNA-1 standard stock solution was 
35.8 ng/µL with a standard deviation of 9.07. The DNA copy number in the standard was 
determined using the following formula:  
Number of DNA copies = [amount of amplicon(ng) x 6.0221 x 1023molecules/mole] 
/[length of DNA amplicon x 660ng/mole x 1x109ng/g] 
Using the mean Nanodrop measurement as the basis, the mean number of DNA copies 
for the stock standard solution was calculated to be 6.84 x 1011 copies of EBNA-1 DNA. 
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To allow for measurement in the linear range of the qPCR machine, the standard was 1:10 
serially diluted as depicted in Table 12.2. This standard was used in all subsequent qPCR 
experiments to calculate EBV copy numbers of unknown samples.  
3’CACAATGTCGTCTTACACCATTGAGTCGTCTCCCCTTTGGAATGGCCCCT
GGACCCGGCCCACAACCTGGCCCGCTAAGGGAGTCCATTGTCTGTT5’ 
Table 12.1. Sequence of qPCR amplified 97bp EBNA-1 fragment from position 389 to 
641 as sequenced by Next Generation Sequencing.  
To optimise the concentrations of qPCR primers and probe used (QIAGEN, US), the 
standard was tested by qPCR initially at 350nM of forward and reverse primer and 180nM 
of the probe, as recommended by the manufacturer. However, it was confirmed that 
primer dimers were seen when the amplicons were visualised on a 3% agarose gel, hence 
the concentrations of the primers and probe were reduced to 200nM and 170nM, 
respectively.  
The standard was tested in qPCR and Cq values were determined as demonstrated in 
Table 12.2. As it was unknown which DNA concentrations were detectable by qPCR, six 
dilutions of the standard were initially tested. Five out of the six dilutions of the standard 
were detected by qPCR, however, only three dilutions (684,000, 68,400 and 6840 DNA 
copies) were successfully replicated. Hence, these three dilutions were used for standard 
curve analysis. Performance of the standard was analysed by standard deviation, variance, 
and coefficient of determination, as given in Table 12.2, and the standard was determined 
to be highly reproducible. The limit of detection of the standard was calculated as 6.84 
copies of EBNA-1 DNA (see 11.6.3 for qPCR calculations). However, it could not be 
consistently detected at this low level every time. The limit of quantification, or the lowest 
concentration of the standard detected consistently in every assay, was 6840 copies of 





log10[DNA copies] Mean Cq Median Standard 
deviation 
Variance R2  
684000 5.84 29.65 29.60 1.02 1.03 0.98 
68400 4.84 32.82 32.8 0.20 0.04 
6840 3.84 36.98 36.97 1.03 1.05 
684 2.84 47.49 47.49 N/A N/A 
68.4 1.84 Undetected N/A N/A N/A 
6.84 0.835 48.55 48.55 N/A N/A 
Table 12.2. Comparison of EBNA-1 standard performance between all qPCR assays. Six 
serial dilutions of the standard were used. The number of amplification cycles, or Cq 
value, was given at each serial dilution of the standard. The standard deviation and 
variance were calculated for Cq values that were detected more than twice. The qPCR 
reader did not detect the standard at concentrations of 684 DNA copy number and 6.84 
DNA copy number more than once, and at 68.4 DNA copy number, the standard was not 
detected at all, as denoted by “undetected” in the table. N/A denoted calculations that 
could not apply to dilutions as they were not able to be detected more than once. 
The qPCR amplification curve in Figure 12.4 represents serial dilutions of the standard 
by a factor of 10. At less than 68.4 DNA copies of EBNA-1, the amplification curve did 
not reach the threshold and hence no Cq value could be determined. The threshold was 
set by the qPCR reader was 100 relative fluorescence units (RFU), however at this 
threshold initial background “noise” was detected in PCR amplification. Hence, the 
threshold was raised to 455 RFU, which was above the initial non-specific detection but 
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less than the lowest standard dilution detected at 6.84 DNA copies. To keep the assay 
consistent, this threshold was used in each qPCR analysis for all samples.  
 
  
Figure 12.4. Standard qPCR amplification curve with relative fluorescence units (RFU) 
plotted against the number of cycles with the threshold in red at 455 RFU. Serial dilutions 
of the standard are demonstrated to 1:107 (equivalent to 68.4 DNA copies). 
 
Amplified healthy control and standard qPCR products were examined by agarose gel 
electrophoresis to determine the specificity of the primers and probe. The qPCR assay of 
the standard only amplified the 97bp target, as demonstrated on the agarose gel in Figure 
12.5. Three healthy control samples were also tested alongside the standard in this 
experiment, however, none of these samples were detected by the qPCR reader. An 
amplified fragment length from the qPCR of healthy control sample 3 was observed on 
the gel Figure 12.5 at 150bp. However, this was not the target 97bp amplicon for this 





Figure 12.5. qPCR amplified healthy control samples and standard in 3% agarose gel with 
a 50bp molecular weight DNA ladder. Lanes 1-3 were healthy control samples and Lane 
4 was the EBNA-1 qPCR standard (97bp). An amplicon was seen in lane 3 (150bp) with 
no amplicons detected in lane 1 and lane 2.  
The standard curve for the four qPCR assays, as depicted for comparison in Figure.12.6, 
were analysed for variance. The variance of the Cq values was on average 0.76 cycles 
between all qPCR standard assays, and the mean standard deviation was 0.75 cycles. 
 
Figure.12.6. Standard curves for all qPCR assays for DNA copy numbers between 6840 
copies and 68,400 copies. The standard was detected twice at lower DNA copies however, 


















Standard curves for all qPCR assays
1 2         3          4 
- EBNA-1 Standard 97bp 
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12.4.2 qPCR analysis of healthy control samples 
Out of 38 healthy control samples, 31 samples were successfully quantified by qPCR. All 
samples were tested in triplicate, however, only fourteen samples were detected in 
duplicate and three samples were detected in triplicate. Stochastic variation was observed 
in the assay and only one sample was reproducible in triplicate.  
The QIAGEN EBV analyte-specific reagent qPCR kit limit of detection was not 
established previously by the manufacturer, however, the limit of detection of EBNA-1 
in healthy control samples in this experiment was 5 DNA copies/2µL, or 2515 DNA 
copies/mL (Table 12.3). The limit of quantification was defined as the lowest DNA copy 
number that could be successfully detected in duplicate. This was 52 DNA copies/2µL, 
or 26,000 DNA copies/mL for the healthy control samples in this experiment. The mean 
was 2.18 x 109 DNA copies/100,000 PBMCs and the median was 7.34 x 105 DNA 
copies/100,000 PBMCs. 
Due to the difference in cell count for each sample used, the EBNA-1 DNA copy number 
was calculated per 100,000 PBMCs to enable accurate comparison between sample 
results, as tabulated in Table 12.3. The median copy number of EBNA-1 in healthy 
controls was 7.34 x 105 DNA copies/100,000 PBMCs. The range between EBNA-1 DNA 
copy numbers was between 23 DNA copies/100,000 PBMCs and 4.34 x 1010 DNA 
copies/100,000 PBMCs. The mean was 2.18 x 109 DNA copies/100,000 PBMCs. The 
mean EBNA-1 DNA copy numbers for the 38 healthy control samples tested were also 

















1 - - - - - - 
2 2.26 x 104 5113.09 - 1.39 x 104 - 1.19 x 104 
3 68.17 3.11 x 104 - 1.56 x 104 - 35.87 
4 - - - - - - 
5 3947.13 1.08 x 107 - 5.41 x 106 - 1.44 x 107 
6 100.15 - - - - 4.34 x 1010 
7 3.16 x 106 - - - - 1.13 x 105 
8 4.78 x 1012 2.65 x 109 - 2.39 x 1012 - 7.96 x 1012 
9 9018.17 5.69 x 106 - 2.85 x 106 - 1.31 x 106 
10 3.11 x 104 - - - - 1.11 x 108 
11 7577.41 1.04 x 105 465.88 3.74 x 104 5.79 x 104 1.46 x 104 
12 - - - - - - 
13 7212.55 15.06 - 3613.80 - 2.03 x 109 
14 1.08 x 109 - - - - 9.82 x 108 
15 3492.96 5.01 x 105 1.01 x 104 1.72 x 105 2.85 x 105 8.59 x 104 
16 - - - - - - 
17 1692.73 - - - - 4.38 x 107 
18 3.76 x 108 - - - - 5.57 x 108 
19 52.44 51.72 - 52.08 - 76.59 
20 6.77 x 107 - - - - 6.45 x 107 
21 5.65 x 105 - - - - 3.890 x 105 
22 8247.69 - - - - 1.38 x 104 
23 1.13 x 109 2825.40 1.65 x 109 3.76 x 108 6.52 x 108 2.26 x 108 
24 - - - - - - 
25 51.99 3408.20 - 1730.10 - 1038.06 
26 1.60 x 106 - - - - 1040.38 
27 - - - - - - 
28 4.18 x 106 43.67 - 2.09 x 106 - 1.72 x 105 
29 35.77 1.17 x 104 - 5871.32 - 396.36 
30 78.75 9.96 x 1010 - 497 x 1010 - 7.58 x 109 
31 1646.07 - - - - 44.49 
32 1.18 x 106 28.13 - 5.90 x 105 - 4.21 x 104 
33 2.06 x 108 - - - - 1.65 x 109 
34 5.03 - - - - 0.38 
35 - - - - - - 
36 16.97 - - - - 23.15 
37 - - - - - - 
38 5.74 x 105 516.92 - 2.87 x 105 - 1.08 x 106 
Table 12.3. EBNA-1 DNA copy numbers of healthy control samples were tested in 
triplicate with qPCR and results are given per 100,000 PBMCs. Yellow shaded samples 
were successfully detected in duplicate and grey shaded samples were successfully 
detected in triplicate. The standard deviation was only given for samples detected in 




Figure 12.7. Mean number of log[EBNA-1 DNA copies] per 100,000 PBMCs quantified 
by qPCR in 38 healthy control patient samples. The range of healthy control samples was 
between log[1.36 DNA copies]/100,000 PBMCs (or 23 DNA copies/100,000 PBMCs) 
and log[10.64 DNA copies]/100,000 PBMCs (or 4.34 x 1010 DNA copies/100,000 
PBMCs). Samples 1, 3, 4, 8, 12, 16, 24, 26, 27, 34 and 35 were not detected by qPCR. 
Note that the sample identification numbers are arbitrary in relation to other graphical 
analysis of samples provided in this study. 
 
12.4.3 qPCR performance 
After amplification by qPCR, the healthy control sample amplicons were tested for 
specificity by visualisation on a 3% agarose gel, as demonstrated in Figure 12.8. The gel 
results enabled comparison between the qPCR results and the amplified fragment length 
to test the specificity of the probe with healthy control samples. The target fragment 
length of 97bp was visualised on agarose gel for healthy control samples that also were 
successfully detected by qPCR. Samples not detected by qPCR, but appeared on the 
agarose gel image, were not 97bp fragments. However, some samples were detected by 
qPCR at copy numbers >1000 DNA copies but did not appear on an agarose gel. 
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The serially diluted standard tested alongside healthy control samples was also visualised 
on an agarose gel (Figure 12.8) after qPCR amplification to confirm probe specificity. 
The fragments were presented at length 97bp between 1:10,000 dilution (6.84 x 107 DNA 
copies) and 1:10billion (68.4 DNA copies). When the dilution was >6.84 x 107 DNA 
copies, a smear was visualised due to the very high concentration of products present. At 
these concentrations, the standard was detected by qPCR. At less than 68.4 copies of 
DNA, the standard was unreliably detected by the qPCR machine and on an agarose gel 
depicted in Figure 12.8, the fragments were not visible when less than 68.4 copies of 
DNA were present. This supported the limit of detection by the qPCR machine.  In the 
absence of a 97bp band on the agarose gel or the presence of bands at higher or lower 














Figure 12.8. qPCR amplicons displayed on 3% agarose gels. Results of two separate 
qPCR experiments are shown including assay standards in 10-fold dilutions. Standard 
dilutions below 1:10billion, equivalent to 68 copies of EBNA-1 DNA, were negative. The 
healthy control samples numbered in red represent duplicate samples. Samples 1, 3, 6, 8, 
13, 16, 17, 26, 27, 30, 34 and 37 all demonstrated strong bands at the expected fragment 
length of 97bp. Note: the numbers of the samples in this figure do not correspond to the 
numbers allocated to samples in other figures/tables. 
- 97bp EBNA-1 DNA 
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The average amplification efficiency of this qPCR assay was determined to be 95.75% 
with a 3.49 amplification cycle (Cq value) change between standard dilutions, as derived 
from the mean slope of the standard curve. This calculation was derived from Bio-Rad 
(126) and as displayed in Figure.16.4, the threshold cycle was plotted against the 
log10[DNA copy number] of the standard with a regression line.  
 
12.5 Quantification of EBER by flow cytometry coupled with fluorescent in situ 
hybridisation (Flow-FISH) 
12.5.1 B lymphocyte enrichment results 
The isolation of B lymphocytes by negative selection from two healthy control PBMC 
samples yielded high retention of B lymphocyte-enriched populations. B lymphocyte s 
are a minor population of PBMCs, hence >50million PBMCs were thawed for each 
sample. The comparative cell count between pre-B lymphocyte isolation and post-B 
lymphocyte isolations for each sample are listed in Table 12.4. The viability of the cells 
was very high (98%) and the percentage of B lymphocytes from PBMCs for samples 1 
and 2 was 8.46% and 19.33%, respectively.  




Viability B Cell % of 
PBMCs 
1 55 x 106 cells 4.65 x 106 cells 98% 8.46% 
2 60 x 106 cells 11.6 x 106 cells 98% 19.33% 
Table 12.4 B lymphocyte enrichment for downstream flow cytometry analysis. Viability 
was high and B lymphocyte counts were 4.65 x 106 and 11.6 x 106 cells respectively for 




12.5.2 LCL flow-FISH results 
The LCLs were used as a positive control for EBER flow-FISH as they are EBV-
transformed cells and hence were expected to harbour EBV in all B lymphocyte clones. 
As expected, EBER RNA was successfully detected in duplicate in LCLs. The initial 
testing of LCLs with flow-FISH resulted in 8380 EBER positive events out of 111,360 
LCLs, which was equivalent to 4.46%. While, not all LCLs were EBV positive, the 
histogram counts and scatterplot of these EBER events confirms a clear positive shift to 
the right, measured by flow cytometry as portrayed in Figure 12.9 (a and c). A similar 
result was demonstrated when this was repeated with the same sample, resulting in 5549 
positive EBER events in 62,385 LCLs, which was equivalent to 5.55% positive EBER 
events. Again, Figure 12.9 (b and d), the EBER events demonstrated a positive shift of 







Figure 12.9. LCL EBER probe Kaluza flow cytometry analysis. The initial testing of 
LCLs with the EBER probe resulted in 4.46% positive EBER events in 111,360 LCLs, as 
illustrated in a) a histogram plot of EBER events as detected by the FITC fluorophore 
channel and b) a scatterplot of side light scatter and EBER with a positive population 
shifted to the right in both the histogram and scatterplot. Similar results were seen when 
the assay was repeated with the same LCL sample (b and d) with 5.55% positive events 




As LCLs are transformed cells, the cell properties are often different to isolated B 
lymphocytes. Hence, it was necessary for the voltages and compensations established for 
the LCL sample to be different from the B lymphocyte samples. The presence of surface 
markers on LCLs was determined. Interestingly, only anti-CD20 and anti-CD38 
antibodies bound the LCLs at 5.95% and 2.65% of events respectively, as depicted in 
Figure 12.10.d-e. The remaining antibodies were not detected by flow cytometry in the 
LCL sample, as illustrated in Figure 12.10.a-c, f. 
 
Figure 12.10. LCL stained with all antibodies event counts as detected by flow cytometry 
and analysed by Kaluza. CD19, CD24, IgD and CD27 populations were not detected as 
depicted in event histogram a), b), c) and f). Histograms d) and e) demonstrate positive 
CD20 and CD38 populations, respectively, by the clear shift to the right. CD20 was 
detected in 5.95% of LCLs and CD38 was detected in 2.65% of LCLs. The dark purple 
represents all events and the blue and magenta shading represent the proportions of 




12.5.3 B lymphocyte phenotyping results 
The antibodies for the B lymphocyte surface markers were tested in single stains by flow 
cytometry analysis in two healthy control PBMC populations to determine surface marker 
expression in B lymphocytes. As summarised in Table 12.4, in the presence of the EBER 
probe, Sample and 1 and 2 had positive events for all antibodies except CD19, which had 
very low binding efficiency. This resulted in difficulty determining positive populations 
for CD19. This was contradicted when the single stain sample for CD19 in the absence 
of the EBER probe was overlayed on the CD19-negative sample with a positive 
population observed (Figure 12.11.a). All positive antibody stains were compared to the 
negative sample and the negative and positive population plots overlayed, as seen in 
Figure 12.11.b-e. The overlay of the positive single stain population for each antibody on 












Table 12.5. Mean percentage of surface marker events in the presence of EBER probe as 
measured by Gallios flow-cytometer comparing PBMC populations and B lymphocyte -
enriched populations from the same healthy control patients.   
In B lymphocyte enriched populations, the antibodies anti-CD20/APC-HC and anti-
IgD/Pe-Cy7 had high binding efficiency, as depicted in Table 12.5. Anti-CD19/PE had 
low binding efficiency for both populations, as demonstrated by the low mean percentage 
of events in Table 12.5. Anti-CD24/PE-Cf594, anti-CD27/BV510, and anti-
CD38/BV421 had inconsistent binding efficiency in the presence of the EBER probe as 
the number of events decreased instead of increasing when the population was B 
lymphocyte enriched. 
 
Mean percentage of cells measured by flow-cytometer for samples in the presence of EBER probe 
Healthy 
Control  
CD19 CD20 CD24 IgD CD27 CD38 
Sample 1 
PBMCs  
0.79% 5.01% 4.75% 4.02% 15.18% 13.24% 
Sample 1 
B cells  





3.41% 7.17% 4.87% 5.49% 50.92% 47.45% 
Sample 2 
B cells  







Figure 12.11. Overlays of positive 
single stain population over unstained 
PBMC populations in the absence of 
EBER probe, as measured by Gallios 
flow-cytometer. The negative 
populations depicted (in red) were 
overlayed on the positive populations 
(in green). Shown from top to bottom 
are the single staining of a) anti-CD19 
antibody labelled with PE, b) anti-CD20 
antibody labelled with APC-HC, c) 
anti-CD24 antibody labelled with PE-
CF594, d) anti-CD27 antibody labelled 
with BV510, e) anti-CD38 antibody 
labelled with BV421, and f) anti-IgD 
antibody labelled with Pe-Cy7, all 
overlayed on negative populations. 
Whilst overlays a) to c) demonstrate 
uniform populations, the overlays for d) 
and e) (CD27 and CD38, respectively) 
displayed equal negative and positive 




12.5.4 B lymphocyte EBER probe results 
EBER RNA in B lymphocyte s was successfully detected by flow cytometry in healthy 
control B lymphocyte -enriched populations and PBMC populations. 4% of the PBMC 
population from Sample 1 were positive EBER events. 5% of the PBMC population from 
Sample 2 were positive EBER events. For the initial testing of Sample 1, 1% of enriched 
B lymphocyte s were EBER positive events, whilst 21% of enriched B lymphocyte s from 
Sample 2 were EBER positive. However, when this was replicated, 31% and 38% of 
enriched B lymphocyte s were EBER positive events from Sample 1 and 2 respectively. 
B lymphocyte enriched samples were tested in duplicate with approximately 1 million 
enriched B lymphocytes in the first test and 5million B lymphocytes in the second. The 
EBER probe was detected in cells in both samples by flow cytometry, as demonstrated in 
Table 12.5. These results were established by histogram overlay of the EBER positive 
population over the EBER negative population, to compare the positive population shift 












Table 12.6. Percentage of EBER-positive cells measured by Gallios flow cytometer. 
Measured positive EBER events as well as positive antibody surface markers that are 
gated by the different B lymphocyte subsets transitional B lymphocytes, naïve B 
lymphocytes, memory B lymphocytes, switched B lymphocytes, non-switched B 
lymphocytes and plasmablasts. The B lymphocyte healthy control samples were tested 
twice, as annotated by (1) or (2). For test (1), 1 million B lymphocytes were analysed and 
for test (2) 5-8million B lymphocytes were analysed. 
 










Healthy control sample 1 
PBMCs 4% 0.02% 0.91% 0% 1.96% 0.02% 0.44% 
B cell (1) 1% 0% 0.86% 0% 0% 0% 
 
0% 
B cell (2) 31% 0.06% 15.89% 0.01% 14.17% 0% 0.49% 
Healthy control sample 2 
PBMCs  5% 0.37% 0.11% 0% 3.56% 0% 1.44% 
B cell (1) 21% 0.01% 14.31% 0.19% 3.13% 0.04% 1.18% 
B cell (2) 38% 0% 34.08% 0.01% 2.75% 0% 0.23% 




Figure 12.12. Overlay comparisons between positive and negative EBER populations. 
Healthy control sample 1 was assessed twice with flow-FISH for positive EBER B 
lymphocytes and overlayed on the negative population in a) and b). Sample 2 was also 
assessed twice with flow-FISH and the positive EBER B lymphocytes were overlayed on 




Using the gating strategy described in the methods (11.8.2 Gating strategy for B 
lymphocyte subsets and EBER probe), the B lymphocyte subsets were gated and the 
EBER ratio between each subset was determined. As demonstrated in Table 12.6,  naïve 
B lymphocytes were the most positive for EBER at an average of 11.03% of EBER-
positive cells with non-switched memory B lymphocytes at an average of 4.26% of 
EBER-positive cells. Immature transitional B lymphocytes, memory B lymphocytes, 
plasmablasts and switched memory B lymphocytes had the lowest average detection of 
EBER events at 0.08%, 0.04%, 0.01% and 0.63%, respectively. These percentages were 
















Figure 12.13. Sample 1 B lymphocyte subsets gated on EBER-positive cells. Using the 
gating strategy described in the methods of this study, B lymphocyte subsets gave 
percentages of EBER positive plasma lymphocytes, plasma blasts, naïve B lymphocytes, 
non-class switched memory B lymphocytes, class-switched memory B lymphocytes, 
immature transitional B lymphocytes and mature memory B lymphocytes out of a total 







Figure 12.14. Sample 2 B lymphocyte subsets gated on EBER-positive cells. Using the 
gating strategy described in the methods of this study, B lymphocyte subsets gave 
percentages of EBER positive plasma lymphocytes, plasma blasts, naïve B lymphocytes, 
non-class switched memory B lymphocytes, class-switched memory B lymphocytes, 
immature transitional B lymphocytes and mature memory B lymphocytes out of a total 






12.6 Comparison of EBV quantitative methods 
To compare assay performance in detection of EBV, two healthy control samples were 
tested with all three techniques ddPCR, qPCR and flow-FISH to compare their 
quantification of EBV. qPCR quantified EBNA-1 in both samples at 1.31 x 106 and 1.72 
x 105 DNA copies/100,000 PBMCs, whilst ddPCR did not detect EBNA-1 in these 
samples, as presented in Table 12.7. EBER was quantified by flow-FISH for these 
samples at 4% and 5% EBER-positive cells in 1million PBMCs. 
 






ddPCR qPCR Flow-FISH 
Sample 1 Not detected 1.31 x 106 4% 
Sample 2  Not detected 1.72 x 105 5% 
Table 12.7 Comparison of three quantitative techniques for EBV in two healthy control 
samples: ddPCR, qPCR and flow-FISH. ddPCR did not detect EBNA-1 in either 









It was proposed that three quantitative methods would be compared for the detection of 
EBV in latency, using EBNA-1 and EBER as targets. Additionally, the ratio of EBV 
copies in B lymphocyte subsets should be quantified and compared. Healthy control 
samples were tested for the presence of latent EBV using i) qPCR, ii) ddPCR and iii) 
flow-FISH. Although only limited number of samples were tested, the quantitative 
technique ddPCR positive control samples were not quantified and the method was unable 
to detect EBV in healthy controls in this experiment. In contrast, qPCR and flow-FISH 
were successful in the detection and quantification of EBNA-1 and EBER, respectively.  
Of note, all results were established for healthy control samples only, as ethics approval 
for MS patient samples was unable to be obtained prior to the completion of this study. 
All further samples discussed are related to healthy controls only unless stated otherwise. 
 
13.1 Analysis of digital droplet PCR (ddPCR) 
13.1.1 Analysis of the use of reverse-transcribed EBNA-1 RNA as a template for 
quantification 
High homology of EBNA-1 with sequences in genomic DNA has been discovered in 
previous research (69,127). Therefore, for EBV quantification, RNA was reverse-
transcribed and utilized as a cDNA template to reduce the likelihood of targeting of 
genomic DNA non-specifically in downstream assays. A study by Tschochner, et al., has 
proven that nested PCR can detect EBV in latency in MS patients, but single round PCR 
amplification from a DNA template was not sensitive or specific enough for EBNA-1 
detection (69 and personal communication). Unfortunately, nested PCR was considered 
to be unsuitable for quantification in ddPCR as only a fraction of the first-round 
amplicons would serve as a template for nested PCR and the repeated exponential 
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amplification in two subsequent PCRs would hinder the accurate calculation of DNA 
copy numbers. Therefore, two-round PCR was deemed unsuitable for the quantification 
of EBNA-1.  
Subsequently, the approach was made to test the sensitivity of ddPCR and to avoid non-
specific amplification by utilizing RNA as a template for cDNA conversion, thus 
avoiding the quantification of genomic DNA homologous to EBNA-1. Furthermore, 
EBNA-1 is constitutively expressed in infected B cells as the EBV genome is coupled to 
the host genome for the distribution of daughter cells during mitosis (128). However, as 
EBNA-1 is also expressed in lytic infection, quantification will occur regardless of the 
EBV lifecycle stage. The distinction between latent and lytic infection would only be 
made by comparing absolute copy numbers with an arbitrary delineation between high 
and low. Alternatively, the addition of a lytic genes involved in viral reactivation from 
latency and replication, such as BZLF1 or BRLF1, for multiplex PCR would serve as a 
control in future experiments. In addition, it was proposed the EBNA-1 RNA load would 
be greater than that of genomic RNA as genomic DNA is not always expressed, unlike 
EBNA-1, therefore reducing the genomic RNA to EBV RNA ratio when initiating with 
an RNA template.  
Purification of RNA was more challenging than predicted. Despite utilization of a 
modified RNA extraction method including an additional DNA digestion step with an 
increased digestion period, DNA was observed when visualised on agarose gel. 
Additionally, Nanodrop spectrophotometry resulted in an absorbance ratio (mean 1.70) 
which was less than the expected pure RNA ratio of 2.00.  
In parallel, the existence of DNA in the RNA samples was confirmed in HLA-C PCR. 
Primers of HLA-C are designed to amplify RNA and DNA at different lengths. 
Significant quantities of DNA were established in the HLA-C PCR agarose gel with 
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fragments observed at multiple lengths, including the expected length of RNA at 1Kbp 
and the expected length of DNA at 3Kbp. Of note, multiple additional shorter fragments 
were amplified in HLA-C PCR for each sample, indicating non-specific amplification in 
HLA-C PCR with off-target primer binding. It was concluded that it may not be feasible 
to eliminate all DNA during RNA extraction using the RNA extraction kit in this assay. 
Consequently, this significantly affected the downstream assay results of ddPCR due to 
non-specific quantification of non-EBNA-1 DNA products. However, the existence of 
DNA in the RNA samples was not a crucial inhibitor of qPCR specificity. 
In theory, if the purity of RNA was very high, the DNA copy number could be determined 
from the original sample PBMC count and related to the concentration of RNA as 
determined by Nanodrop spectrophotometry (see 11.2 Methods). However, the Nanodrop 
could not be used to analyse RNA extraction products for quantification due to the 
impurity of the RNA (absorbance ratio of 1.70) and the spectrophotometer inaccuracy at 
concentrations less than 40µg/mL. Improvement of the RNA purity by further increasing 
the number of DNA digestion steps, was not anticipated. As an alternative option to the 
Nanodrop, the use of Agilent 2100 Bioanalyzer for RNA quantification was speculated 
to be a more accurate technique. The bioanalyzer uses the fluorescence of RNA molecules 
in a microfluidic chip to determine the size and mass of the product. However, an RNA 
reference standard and a microfluidics chip would be required and could not be tested 
within the time frame of this project. 
The reverse-transcription of RNA into cDNA was initially tested using random hexamers 
as well as oligo dT primers in this assay. Early in testing, it was determined that oligo dT 
primers successfully supported reverse-transcription of RNA, whereas random hexamers 
failed. Hence, oligo dT primers were utilized in reverse-transcription for the remainder 
of RNA sample conversions. Failure of the random hexamers may be due to how they 
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prime at random on RNA, resulting in small segments of cDNA that may not include the 
full target EBNA-1 segment (850bp for ddPCR primers and 97bp for qPCR primers). 
Contrastingly, oligo dT primers start at the poly-A tail of RNA, where reverse 
transcriptase also starts, and result in far larger segments. Consequently, oligo dT primers 
were utilized to reverse transcribe cDNA templates for the downstream assays of ddPCR 
and qPCR. 
13.1.2 Investigation of ddPCR results 
During ddPCR testing of two healthy control samples, the ddPCR reader did not quantify 
EBNA-1, but successfully detected one LCL sample and the Daudi positive control 
dilutions 1:1000 and 1:10,000. This assay would need to be repeated for confirmation, 
but it can be concluded that the negative results indicate the EBNA-1 DNA copy numbers 
in the healthy control samples were too low for the ddPCR reader to detect. Hence, the 
technique was determined to not be sensitive enough, considering the positive control, 
Daudi, was detected by ddPCR. The detection limit for ddPCR was determined to be 282 
EBNA-1 DNA copies, as detected in the Daudi dilution of 1:10,000. Contrastingly, 
previous studies demonstrated ddPCR to be a sensitive method for EBNA-1, with a limit 
of detection at 3.12 log10 copies/mL (129). Nevertheless, next to the low sensitivity found 
in this assay, poor specificity for the target EBNA-1 gene amplification was 
demonstrated. Despite the aforementioned genomic DNA present in the RNA samples, it 
was predicted amplification and quantification of the target EBNA-1 would be successful 
as a result of the reduced amount of DNA. However, one of the two LCL positive controls 
in early testing proved this was not the case as double bands (~850bp and 500bp) were 
observed on agarose gel after ddPCR amplification. It was later confirmed by the negative 
EBNA-1 sequencing results that the ddPCR EvaGreen dye and in-house primers were not 
specific for EBNA-1 alone. As non-specific amplification would still be quantified by 
ddPCR, this method was unsuitable for further use with the current procedure.  
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A possible improvement of the ddPCR assay may be to use the qPCR primers and probe 
with the ddPCR reader, a probe-specific master mix and ddPCR probe oil instead of 
DNA-specific EvaGreen Supermix. Previous research has found ddPCR to be an accurate 
method of EBNA-1 quantification (129) however it has also been confirmed previously 
to be no more accurate than qPCR (117). Due to time and resource constraints, repeating 
the assay with different primers and probe was not pursued in the confines of this 
experiment. 
13.2 Analysis of quantitative PCR (qPCR) 
13.2.1 Investigation of qPCR results 
Using RNA as a template for cDNA was proposed to reduce the likelihood of non-specific 
amplification, as the alanine-glycine rich region in EBNA-1 is homologous with multiple 
sites on the human genome (69). Despite the presence of DNA in the RNA samples, the 
qPCR technique was 100% EBV specific and the qPCR reader did not detect non-specific 
amplification; only the correctly amplified target of 97bp EBNA-1. This was enabled by 
the combination of a specific FAM probe with primers, which together are highly specific 
for the EBNA-1 sequence. Confirmation by agarose gel of this specificity was determined 
by band length corresponding to qPCR detection. Though some samples did produce 
fragments at lengths other than 97bp, or no fragments at all, these were not detected by 
qPCR. Ergo, specificity of the qPCR for EBNA-1 was established to be excellent. 
Regarding the sensitivity of the qPCR technique, it was found only 31 out of 38 healthy 
control samples could be detected. However, while all samples were tested in triplicate, 
only 14 samples were successfully duplicated, and merely three samples detected in 
triplicate. Although not all samples could be amplified with qPCR, the limit of detection 
of this assay was determined to be excellent with a minimum of 5 DNA copies/2µL or 
2515 DNA copies/mL, and the limit of quantification (as defined by lowest DNA copy 
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number in successfully replicated samples) was 52 DNA copies/2µL, or 26,000 DNA 
copies/mL. In comparison to previous studies (114,115), this assay was determined to be 
sensitive, however, this sensitivity was not reproducible for all samples. Differences in 
technical factors, such as choice of nucleic extraction method, target latent gene, and 
different qPCR thermocyclers made it difficult to directly compare the results of latent 
EBNA-1 quantification to aforementioned studies (114,115). As previous studies have 
measured the DNA copy number/mL, the comparison with the results of this study was 
not complete due to PBMC count variation prior to RNA extraction. Hence, whilst the 
detection limit was low, the reproducibility of detection was poor. A suggested 
improvement would be the incorporation of an automated robotic pipetting setup to 
minimize error and reduce variability within results. 
To further support the accuracy of the primer and probe kit, the qPCR primer 
amplification efficiency (a rate of accurate amplification for every cycle) was determined. 
With a very high amplification efficiency (95.75%, as calculated in Methods) and a low 
difference in Cq value change (3.49 cycles) between standard dilutions, the assay was 
determined to be very specific. Consequently, this reinforced qPCR as an accurate assay 
accounting for minor variation between standards 
Stochastic variation of the qPCR assay resulted in variable DNA copy numbers in the 
healthy control samples. For the three healthy control samples successfully tested in 
triplicate by qPCR, there was a very high standard deviation for the EBNA-1 DNA copy 
numbers (between 5.79 x 104 and 6.52 x 108 DNA copies). As a consequence, 
reproducibility of the sample DNA copy numbers was significantly limited. However, 
high standard deviation was expected, as qPCR utilizes relative fluorescence, and as such 
Cq values varied between assays. However, it was still considered to be absolute 
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quantification as a positive control standard with a known copy number was included in 
each assay, allowing EBNA-1 DNA copy numbers to be calculated. 
Initially, the threshold used in the qPCR Bio-Rad CFX Manager software (Bio-Rad) was 
the default on the qPCR reader, (100 relative fluorescence units (RFU)). After the first 
two to three cycles of PCR, this default threshold was determined, allowing the initial 
non-specific amplification to be accounted for. The threshold was later determined to be 
455 RFU as a consequence of early breaching by the healthy controls, and this threshold 
was then used for all future qPCR assays. Using an unoptimized threshold increased the 
possibility of inaccurate quantification due to early breaching. A number of samples were 
observed to breach the threshold at very low Cq values, resulting in large DNA copy 
numbers, such as 1.54 Cq (or >5trillion DNA copies). This occurred despite no 
amplification products appearing tested on an agarose gel, suggestive of a false positive. 
For this reason, the threshold was later raised to 455 RFU, which was determined to be 
above all early noise but low enough for the standard to be detected to 6.84 DNA copies. 
Fortunately, the threshold could be adjusted post-PCR and hence the correct quantities of 
EBNA-1 in these samples were successfully recorded. When the threshold was adjusted, 
the Cq value of the standard and the healthy control samples changed. Yet, as this study 
was looking at absolute quantification, not relative quantification, it was necessary to use 
a consistent threshold; thus, an optimized threshold was determined.  
Inhibition of qPCR by sample-specific factors, biological products, and non-biological 
products was reduced at every step. Hindrance of the assay by biological products was 
limited by increasing RNA purity during RNA extraction with extended DNase treatment, 
and aseptic technique to eliminate contamination. Additionally, sample-specific 
inhibition was reduced by using the same sample source type for all qPCR assays, which 
was PBMCs extracted from whole blood and limited freeze-thawing. Furthermore, 
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possible impediment of the qPCR by non-biological compounds, such as chemical 
reagents, was also diminished by the multiple wash steps of the silica membrane in the 
RNA spin column. This ensured only nucleic acid remained on the membrane by the final 
step. 
 
13.3 Analysis of flow cytometry coupled with fluorescent in situ hybridisation 
(flow-FISH) 
Experimental testing for flow-FISH was limited by resources. The EBER probe kit only 
supplied enough reagents for 20 reactions. As a result, only two healthy control samples 
were tested by flow-FISH in triplicate after assay optimisation and control sample testing. 
Additionally, EBV infected cells in latency were expected to be very rare. A previous 
study estimated 1% of all B lymphocytes to be latently infected with EBV (130). 
Therefore, the decision was made to enrich B lymphocytes before testing. The enriched 
B lymphocyte populations were 4.65 x 106 cells for one sample and 11.6 x 106 cells for 
the second sample, limiting the number of times the assay could be repeated. Due to this 
restriction of resources, the single stains for the antibodies and probe were initially tested 
on healthy control PBMC populations instead of enriched B lymphocytes. As B 
lymphocytes are present in PBMC populations, the voltage and compensation settings 
would be nearly identical. 
For experimental optimisation, the voltage for the flow cytometer was adjusted in single 
stained tubes and compensation was calculated. The voltage was adjusted to allow 
distinction between positive and negative populations within the measurable window. 
However, positive and negative distinctions in the single stains relied on the presence of 
positive populations, high binding affinity of the antibody/probe and a negative unstained 
population. As enriched B lymphocytes were used there were no negative cells present to 
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serve as a control. Without a truly positive population to compare against the negative, it 
was very difficult to confirm if the population was positive. The experiment was therefore 
repeated using PBMCs to help with the initial voltage adjustments and gating strategy. A 
number of positive and negative populations were easier to distinguish based on the 
antibody used. For example, positive populations of B lymphocytes with surface markers 
CD20, IgD, and CD38, could be more clearly discriminated compared to those with very 
minimal positive shift, such as CD19, CD24, and CD27. This small shift was suspected 
to be attributable to antibody-specific factors such as resolution, spillover and target 
affinity. Resolution influences the brightness of fluorophores, and it is known that 
BV421, BV510, PE and PE-Cy7 fluorochromes (for anti-CD38, anti-CD27, anti-CD19, 
and anti-IgD, respectively) are very bright. However, this was inconclusive as anti-CD19 
was labelled with PE and anti-CD27 was labelled with BV510, both of which are very 
bright fluorophores, yet these antibodies were difficult to distinguish from negative 
populations. When compared to moderate or dim fluorophores, such as FITC and APC-
HC for EBER and anti-CD20 respectively, brighter fluorophore events are more readily 
detectable than dimmer ones, which can affect quantification and measurement. This may 
have influenced the very high number of events detected for the anti-CD38/BV421 and 
anti-IgD/PE-Cy7 antibodies compared to others. Due to this uncertainty in positive shift, 
it was difficult to determine an absolute quantification for B lymphocyte subset events. 
Investigation of the flow-FISH output for EBER-positive healthy control cells was 
successfully determined using Kaluza software to distinguish positive populations from 
negative populations. However, difficulties arose as a result of the low number of positive 
events for surface antibody and EBER probe targets, which caused only a slight positive 
shift and made gating difficult. To aid in distinguishing the positive and negative 
populations for EBER, the populations were compared by overlaying the positive over 
the negative population using Kaluza software. Further, to ensure an accurate 
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representation for both populations, the flow events were gated so there were equal 
number of cells in each population. With this overlay, the positive population was 
distinguished by the slight shift to the right in comparison to the negative population. 
As aforementioned, the most significant limitation of flow-FISH was determined to be 
the low binding affinity of anti-CD19 in the presence of the EBER probe, which prevented 
the phenotyping of memory B lymphocytes, and subsequently inhibited the analysis of 
EBER in memory B lymphocytes. To troubleshoot the antibody, anti-CD19 was tested as 
a single stain immediately after fixation without proceeding to the permeabilization and 
hybridization steps, and it was determined that the anti-CD19 antibody functioned in the 
absence of these protocols. However, it was inconclusive whether this was due to the 
permeabilization step, the EBER probe hybridization step, or how these techniques may 
have affected the antibody surface marker. Availability of CD19 surface markers may 
have been altered by these techniques and the low binding affinity of anti-CD19 may be 
attributable to the process of fixation and permeabilisation. An improvement could be to 
optimise the anti-CD19 antibody for use in conjunction with the EBER probe technique. 
Possible adjustments could include increased anti-CD19 concentration, longer staining 
times, or an alternative fluorophore to be attached to anti-CD19. 
Gating of EBER-positive naïve B lymphocytes, and their non-class switched memory B 
lymphocyte derivatives, was enabled by the population shift of positive EBER cell 
populations. Naïve B lymphocytes and non-class switched memory B lymphocytes may 
have had a positive result as a consequence of the nature of EBV latency: EBV is known 
to reactivate and exit latency, however the underlying mechanism is unknown (105). EBV 
reactivation could potentially increase the capacity of EBV to infect naïve B lymphocytes, 
thus reinitiating the cycle. Consequentially, naïve B lymphocytes are forced into 
transition by EBV to become memory B lymphocytes (105). Re-activation of EBV is a 
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potential explanation for the presence of EBER RNA in naïve non-class switched memory 
B lymphocytes. 
In an individual with latent EBV infection, it was expected that memory B lymphocytes 
would be the B lymphocyte subset with the highest level of EBER. Previously, studies 
have found EBV to persist latently in memory B lymphocytes after acute infection has 
ceased (131). However, aforementioned studies have only determined EBER presence in 
lytic infection or EBV-transformed cell lines using flow-FISH, but not in latency 
(118,119). Nonetheless, in this experiment, the memory B lymphocytes could not be 
gated by flow-FISH analysis as a result of low binding affinity of the anti-CD19 antibody. 
Therefore, it was possible the memory B lymphocytes in the samples were positive for 
EBER, but it was impossible to determine this from the results.  
Although LCLs proved to be a suitable positive control for EBER, it required a different 
voltage and compensation setting from the healthy control sample. Thus, it was not 
possible to compare the results of the LCL positive events and the healthy control positive 
events directly by overlay. LCLs were a poor positive control for antibody-surface marker 
binding, and only very limited antibodies bound LCL surface markers. The low binding 
affinity may be attributed to downregulated LCL surface marker expression during EBV 
transformation. This was not unexpected, but due to time constraints, a more effective 
substitute for LCLs was not determined. As surface marker and EBER expression is 
variable between PBMC, enriched B lymphocytes, and LCL populations, flow cytometric 
analysis was not directly comparable. For the reason that cell populations were detected 
at different positions, it was not possible to overlay each for a direct comparison of 
positive EBER populations. As a result, suitability of the LCL positive for confirmation 
of the EBER probe function in this assay was established, however it was determined to 
be unsuitable for B lymphocyte surface marker validation. 
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Originally, the gating strategy used in this flow cytometry assay was designed by Dr. 
Monika Tschochner to be inclusive of a CD45 antibody labelled with a FITC fluorophore. 
CD45 is a universal lymphocyte surface marker and would have been highly suitable for 
gating lymphocytes such as memory B lymphocytes. However, the EBER probe was 
labelled with FITC and hence the antibody was swapped for the probe. As the gating 
strategy was already limited by the low binding affinity of anti-CD19, the gating of some 
B lymphocyte subsets such as memory B lymphocytes (CD45+, CD19+, CD27+), was 
more challenging in the absence of anti-CD45. An additional improvement to the gating 
strategy would be to adjust the flow panel to include an additional marker, such as 
CD138+ in the panel to help in detecting plasmablasts.  
Altogether, flow-FISH proved to be sensitive and specific enough to detect EBV-positive 
B lymphocyte subsets, however the protocol needs to be further modified to enable 
reliable detection of all B lymphocyte subsets in sufficient quantity. 
 
13.4 Future directions 
Presently, qPCR and flow-FISH have been determined to be successful in specifically 
detecting EBV infected lymphocytes. In future research, the qPCR technique will need to 
be further optimised, particularly to improve reproducibility and reduce variability. qPCR 
variability can be attributed to many factors, but human error can be diminished if 
pipetting is in a non-manual platform such as a robotic pipetting machine. At this point, 
qPCR has only been sensitive enough to detect latently infected cells in a majority of 
healthy control samples. It is uncertain if qPCR is suitable for the detection of EBNA-1 
in B lymphocyte subpopulations, where it is predicted the EBNA-1 copy number will be 




One of the major caveats of the flow-FISH technique was the interference of the EBER 
probe protocol with the anti-CD19 antibody. The flow-FISH technique would be 
improved with the use of a different fluorochrome-coupled anti-CD19 antibody, or by 
using an alternative marker to CD19 to distinguish memory B lymphocytes and 
plasmablasts in B lymphocyte phenotyping. 
Once the B lymphocyte subset phenotyping is confirmed, the MS patient samples could 
be analysed using flow-FISH for determination of a ratio between EBER-positive B 
lymphocyte types compared to healthy controls.  
Ideally, after both qPCR and flow-FISH techniques are optimized, B lymphocytes could 
be enriched and then flow sorted according to their surface antigen expression. Hence, 
the B lymphocyte subsets could be separately analysed using qPCR for confirmation of 
EBNA-1 quantities within each subset. 
Upcoming research will be commenced with testing MS patient samples at different 
disease stages to elucidate EBV quantities in different B lymphocyte subsets. These 
quantities will be compared between acute and early MS, relapsing remitting MS (with 
and without acute symptoms), primary-progressive MS, patients without symptoms over 
10 years (benign MS), and healthy control samples. 
In the expectation of identifying an EBV infected B lymphocyte subset, the additional 
surface marker, or combination of surface markers indicative of EBV infected B 
lymphocytes will be characterized. Subsequently, the predicted surface marker or 
combination of surface markers will enable flow sorting of the target EBV infected B 
lymphocyte subset. Therefore, live cells can be harvested, and fixation protocols can be 
avoided, enabling further phenotyping of their antigen-presenting cell characteristics. For 
determination of MHC characteristics and antigen-related behaviour in this B lymphocyte 
subset, they would be exposed to T lymphocytes from MS patients and healthy controls. 
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In addition, B lymphocyte depletion therapy could utilize the determined EBV-infected 
B lymphocyte subset in MS patients as a target for a new therapeutical approach. 
Currently, B lymphocyte depletion therapy targets all CD20 lymphocytes, which are the 
majority of all B lymphocytes (45). Depletion of all B lymphocytes can cause some 
adverse side effects, such as allergic reactions and infections (45). This therapy could be 
modified to be more specific, based on the EBV-infected B lymphocyte subset population 
to be determined, in such a way that a surface marker cocktail would only deplete the 
target population rather than all B lymphocytes. Subsequently, MS patients would 
experience less adverse side effects as only a minor proportion of lymphocytes would be 
depleted. Trialled clinically, this treatment could further confirm the association between 
EBV and MS through the depletion of the virus’ most prominent carrier.  
Thus, the research initiated in this project could progress to enable the confirmation of a 
biomarker for MS patients as well as an objective for B lymphocyte depletion therapy. 
Although there is some further research required to reach this aim, future therapy for MS 
patients with reduced side effects as a result of targeted EBV infected B cell depletion is 







This is the first reported study of quantification of EBV in latency, targeting EBNA-1 and 
EBER in healthy control samples, using a combination of ddPCR, qPCR and flow-FISH. 
In conclusion, comparison of these three assays identified ddPCR as unsuitable with its 
current protocol for accurate EBV quantification.  
Contrastingly, qPCR was ascertained to be 100% specific for EBNA-1 and very sensitive, 
allowing accurate quantification in latency with as little as ~52 DNA copies. However, 
significant variation between healthy control sample DNA copy numbers was observed 
in samples tested in triplicate and this disparity will have to be overcome. Despite this, 
qPCR was still proven to be a technique with absolute quantification, due to the 
reproducibility of the standard DNA detection.   
Furthermore, the novel flow-FISH technique successfully detected EBER in 28-38% of 
healthy control B lymphocytes. Sensitivity of this method was verified when testing an 
enriched B lymphocyte population, as it increased the likelihood of EBER detection. 
EBER was found to be in greatest proportions in naïve B lymphocytes and non-class 
switched memory B lymphocytes, which was in contrast to current literature, as memory 
B lymphocytes were identified to be EBV infected when testing LCLs. Of note, LCLs are 
known to behave contrarily to enriched B lymphocyte populations and resemble the 
characteristics of cancer cells, including altered cell surface marker expression.  
Interestingly, whilst transformation of B lymphocytes into LCLs is initiated by EBV, 
several studies observed that LCLs often do not harbour the EBV genome after passage 
or clonal expansion in patient cells. Low detection of memory B lymphocytes was 
attributed to the low binding affinity of anti-CD19 antibody in the presence of EBER, 
hence it cannot be ruled out that memory B lymphocytes represent the B lymphocyte 
subset with the highest EBER copy number. 
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The quantification of EBNA-1 in healthy control samples is an essential step and will be 
optimized in future studies. In addition, further research will enable more insight to be 
gained into the role of EBV infected B lymphocyte subsets in the context of MS. This 
will enable characterization of EBV infected B lymphocyte subsets and hopefully 
culminates in a surface marker panel to be utilized as a biomarker for MS in the future. 
Current MS therapies, especially B lymphocyte depletion, could be improved with 
specific targeting of surface markers based on the methods utilized in this project. 
Specific B lymphocyte subpopulation depletion would reduce adverse side effects with a 
more target approach. In addition, the surface marker panel may also serve as a biomarker 
of MS before the initial symptoms occur. This exciting research could potentially 
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